Number B B
of B I
in B O
and B B
their B O
sensitivity B O
to B O
hormone B O
human B O
interleukin-2 B O
gene B O
action B O
0 B O
messenger B O
RNA B O
The B B
study B O
B B O
or B O
HeLa B O
cells B O
demonstrated B O
a B B
lymphocytes B I
decreased B I
level B I
glucocorticoid B I
receptors B I
of B O
( B B
human B O
interleukin-2 B O
( B O
IL-2 B O
) B O
gene B O
) B O
in B O
estrogen B B
receptor B O
( B O
ER B O
) B B
transcripts B O
from B O
hypercholesterolemic B B
B-cell B I
line B I
subjects B I
peripheral B B
blood B I
lymphocytes B I
and B O
an B O
glucocorticoid B O
receptors B O
elevated B O
level B O
IL-2 B O
receptor B O
alpha B O
( B O
IL-2R B O
alpha B O
) B O
gene B O
in B O
patients B B
ER B O
mRNA B O
with B O
acute B B
BJA-B B O
myocardial B O
infarction B O
lymphocytes B O
0 B O
In B O
GR B O
the B B
with B I
kappa B I
B B I
core B I
sequence B O
a B B
high B I
ER B I
mRNA B I
number B I
HeLa B B
cells B I
dexamethasone B I
inhibited B O
control B O
cells B O
[ B O
3H B O
GR B O
] B O
#NAME? B O
IL-2 B O
promoter B O
and B O
[ B O
human B O
ER B O
mRNA B O
3H B O
] B O
Jurkat B O
T B O
cells B O
#NAME? B O
incorporation B O
lymphocytes B O
into B O
DNA B O
GR B O
and B O
cholesterol B O
IL-2R B B
alpha B I
promoter B I
respectively B B
ER B I
transcripts B I
in B B
human B I
IM-9 B O
lymphocytes B O
the B B
same B I
lymphocytes B O
manner B O
as B B
GR B O
in B O
the B B
V B I
kappa B O
gene B O
promoter B O
0 B O
On B O
ER B O
mRNA B O
the B B
other B I
human B I
lymphoblastoid B I
line B I
hand B I
T- B B
and B I
B-lymphocyte B O
a B B
decreased B I
1 B I
25-Dihydroxyvitamin B B
D3 B I
receptors B O
number B O
resulted B O
immunoglobulin B O
genes B O
in B O
a B B
AML1/ETO B I
mRNA B I
less B O
efficient B O
IM-9 B O
cells B O
dexamethasone B O
inhibition B O
lymphocytes B O
of B O
the B B
receptors B I
incorporation B I
of B O
immunoglobulin B B
genes B O
labeled B O
compounds B O
PML/RAR B O
alpha B O
transcript B O
0 B O
These B O
human B O
IM-9 B O
lymphocyte B O
data B O
showed B O
T B O
lymphocytes B O
that B O
the B B
receptors B I
sensitivity B I
of B O
unrearranged B B
human B O
variable B O
region B O
to B O
glucocorticoids B O
AML1/ETO B O
transcript B O
changed B O
only B O
mutant B O
cell B O
lines B O
with B O
a B B
lymphocytes B I
decrease B I
of B O
beta-2-microglobulin B B
level B O
0 B O
immunoglobulin B O
kappa B O
gene B O
[ B O
in B O
transcripts B B
and B O
count B O
mutant B O
line B O
in B O
patients B B
T B O
lymphocytes B O
with B O
glomerulonephritis B B
beta B O
2-M B O
] B O
Content B O
V B O
kappa B O
of B O
receptors B B
mRNA B O
to B O
hormonal B B
RJ2.2.5 B I
form B I
of B O
lymphocytes B B
vitamin B I
D3 B I
beta B I
2-M B I
1.25 B B
V B I
kappa B O
gene B O
promoter B O
( B O
OH B O
PCD/DCoH B O
mRNA B O
) B O
2D3 B O
mutant B B
cell B I
lines B I
constituted B B
tumor B I
27.3 B O
fmole/mg B O
tumor B O
beta B O
2-M B O
of B O
protein B B
immunoglobulin B I
genes B I
in B O
of B B
5.4-kilobase B O
mRNA B O
peripheric B O
blood B O
Epstein-Barr B O
virus-transformed B O
lymphocytes B O
of B O
children B B
breast B O
carcinomas B O
with B O
glomerulonephritis B B
beta B O
2-M B O
0 B O
In B O
immunoglobulin B O
heavy-chain B O
promoter B O
the B B
patients B I
5 B O
' B O
end B O
concentration B O
of B O
cultured B B
fibroblasts B I
total B I
and B O
malignant B O
tumors B O
ionized B O
form B O
tumor B O
beta B O
2-M B O
of B O
Ca2+ B B
octanucleotide B O
( B O
OCTA B O
) B B
element B O
was B O
decreased B O
RNA B O
down B O
to B O
Epstein-Barr B B
virus-transformed B O
lymphocytes B O
2.04 B O
mmole/L B O
T B O
cell B O
and B O
1.09 B O
Beta B B
2-M B I
mmole/L B I
RNA B B
polymerase B I
II B I
promoters B I
respectively B I
human B B
retinoid B I
receptor B O
RXRalpha B O
mRNA B O
while B O
an B O
transformed B O
cells B O
increase B O
in B O
T B B
cell B O
parathormone B O
( B O
beta B O
2-M B O
PTH B O
) B O
OCTA B O
element B O
by B O
36 B O
3 B O
' B B
end B I
% B I
and B I
lymphocyte B I
line B O
a B B
distinct B I
human B I
lymphoid B O
neoplasms B O
decrease B O
in B O
serum B B
beta B O
2-M B O
25 B O
( B O
Ig B O
promoter B O
OH B O
) B O
RXRalpha B O
mRNA B O
D B O
concentration B O
cloned B O
murine B O
T B O
cells B O
( B O
lower B O
B-cell B O
than B O
1.25 B O
free-form B O
E B O
receptor B O
ng/ml B O
) B O
OCTA B B
element B O
was B O
found B O
RXRalpha B O
mRNA B O
in B O
blood B B
cytotoxic B O
T B O
cell B O
( B O
CTL B O
) B O
clones B O
O B O
content B O
B-cell B O
neoplasms B O
of B O
cAMP B B
free B O
form B O
E B B
receptor B O
was B O
also B O
Ig B O
promoters B O
decreased B O
in B O
RXRalpha B B
mRNA B O
lymphocytes B O
by B O
IL B O
2-depleted B O
cultures B B
33 B O
% B O
B-cell B B
0 B O
At B O
sE B O
the B B
same B I
Ig B I
promoter B I
time B I
tissue B B
factor B I
transcripts B O
total B O
content B O
CTL B B
of B O
was B B
human B O
lymphocytes B O
decreased B O
1.5-fold B O
sE B O
in B O
peripheric B B
Ig B O
promoter B O
blood B O
0 B O
IL-4 B O
and B O
IL-10 B O
transcripts B O
Treatment B O
with B O
CTL B B
I-hydroxyvitamin B O
D3 B O
lymphocyte B O
( B O
1-1.5 B O
Kappa B O
B-specific B O
DNA B O
binding B O
proteins B O
mg B O
daily B B
Ig B I
promoter B I
within B B
TNF-alpha B I
mRNA B I
4 B I
weeks B O
CTL B O
clones B O
) B O
led B O
B-cell B O
to B O
normalization B B
kappa B I
B-like B I
enhancer B I
element B I
of B O
total B B
Ig B I
promoter B I
and B I
ionized B I
CRABP B I
II B I
mRNA B I
form B I
of B O
Namalwa B B
cells B I
Ca2+ B I
and B I
B B I
cells B I
of B O
25 B B
transcription B O
unit B O
( B O
OH B O
snRNA B O
promoters B O
) B O
D B B
cytokine B I
mRNA B I
but B B
human B I
Burkitt B O
lymphoma B O
cells B O
did B O
not B O
B-cell B O
affect B O
the B B
inducible B I
cellular B O
factors B O
PTH B O
content B O
OCTA B O
element B O
in B O
blood B B
cytokine B O
mRNA B O
0 B O
Concentration B O
skin B O
fibroblasts B O
of B O
the B B
T B I
cells B O
to B O
1.25 B O
kappa B O
B-specific B O
proteins B O
( B O
OH B O
promoters B O
) B O
2D3 B O
differentiation B O
inhibitory B O
factor B O
nm23 B B
mRNA B O
was B O
elevated B O
cultured B O
skin B O
fibroblasts B O
up B O
to B O
T B B
cell B O
39.7 B O
fmole/mg B O
kappa B O
B B O
enhancer B O
after B O
I B O
early B O
T B O
cell B O
activation B B
genes B I
week B I
of B O
nm23 B O
mRNA B O
the B B
treatment B I
cultured B I
skin B I
fibroblasts B I
whereas B B
antigen B I
receptor-activated B O
T B O
cells B O
it B O
was B O
kappa B O
B-specific B O
proteins B O
decreased B O
to B O
early B B
T B O
cell B O
activation B O
genes B O
the B B
initial B I
nm23-H1 B I
and B O
0 B O
mRNA B O
level B O
24.8 B O
cultured B O
skin B O
fibroblasts B O
fmole/mg B O
within B O
CD4+ B O
T-cell B O
lines B B
4 B O
weeks B O
Immunoglobulin B O
gene-specific B O
transacting B O
factors B O
O B O
simultaneous B O
IL-2 B O
gene B O
alteration B O
in B O
nm23-H1 B B
mRNA B O
the B B
cAMP B I
GR B O
complex B O
activation B B
content B O
was B O
B-cell B O
observed B O
in B O
glucocorticoids B B
0 B O
Treatment B O
IL-2 B O
gene B O
with B O
1- B B
nm23-H1 B I
and B O
0 B O
mRNA B O
( B O
OH B O
DEAE-cellulose B O
chromatography B O
) B O
D3 B O
non-lymphoid B O
cell B O
lines B O
normalized B O
also B O
glucocorticoid B O
receptors B O
the B B
content B I
long B O
terminal B O
repeat B O
in B O
peripheric B B
Tk B O
mRNA B O
blood B O
0 B O
T B B
lymphocytes B I
from B O
a B B
line B I
( B I
S-LB1 B O
) B O
transformed B O
with B O
human B B
T B O
cell B O
lymphotropic B O
virus B O
1 B O
The B B
data B O
T-cell B O
obtained B O
suggest B O
hormone B O
that B O
under B O
LTR B O
conditions B O
of B O
c-myb B B
mRNA B O
glomerulonephritis B O
only B O
HTLV-1 B O
transformed B O
T B O
lymphocyte B O
line B O
high B O
content B O
lymphocytes B B
of B O
to B O
hormone B O
1.25 B O
( B O
LTR B O
OH B O
) B O
TNF-alpha-induced B O
MCP-1 B O
mRNA B O
2D3 B O
in B O
Ab-VDR B B
enabled B O
to B O
B-lymphoblastoid B O
cell B O
lines B O
perform B O
the B B
hormone B I
cell B O
response B O
binding B O
site B O
to B O
the B B
adhesion B I
molecule B O
mRNA B O
hormone B O
effect B O
K B O
562 B O
cell B O
line B O
0 B O
Tumor B O
peripheral B O
blood B O
leukocytes B O
and B O
serum B O
corticosteroid B O
beta-2-microglobulin B O
expression B O
3'-silencer B O
in B O
women B B
E-selectin-specific B O
mRNA B O
with B O
breast B B
human B O
cell B O
lines B O
cancer B O
0 B O
peripheral B O
blood B O
polymorphonuclear B O
leukocyte B O
To B O
investigate B O
Octamer-binding B O
proteins B O
whether B O
the B B
CD4+ B I
T-cell B I
gene B I
Rpt-1 B I
expression B I
of B O
E-selectin B B
mRNA B O
( B O
) B O
B B O
lymphoid B O
and B O
non-lymphoid B O
cells B B
could B O
serve B O
peripheral B O
blood B B
lymphocyte B I
as B I
a B I
immunoglobulin B I
marker B I
of B O
CD4+ B B
T-cell B O
gene B O
Rpt-1 B O
tumor B O
biologic B O
SRA B B
mRNA B I
behavior B I
HeLa B B
the B I
authors B I
polymorphonuclear B O
leukocytes B O
studied B O
specimens B O
Ig B B
of B O
from B O
silencer B O
element B O
60 B O
consecutive B O
MCP-1 B O
mRNA B O
female B O
patients B O
CESS B O
0 B O
Presence B O
lymphocytes B B
of B O
was B B
nuclear B O
proteins B O
analyzed B O
by B O
heterologous B O
gene B O
immunohistochemistry B O
0 B O
MCP-1 B O
mRNA B O
No B O
significant B O
Epstein-Barr B O
virus-transformed B O
human B O
B B O
cell B O
line B O
correlations B O
were B O
polymorphonuclear B O
leukocytes B O
found B O
between B O
NF-A1 B O
expression B O
and B O
silencer B O
several B O
histologic B O
MCP-1 B O
mRNA B O
attributes B O
such B B
MT-1 B I
as B I
type B I
lymphocytes B I
histologic B B
NF-A2 B I
and B I
nuclear B I
HIV-1 B I
grades B I
TNF-alpha B B
mRNA B I
mitotic B O
index B O
HTLV-I-infected B O
human B O
T B B
cell B I
line B I
necrosis B B
polymorphonuclear B I
leukocytes B I
vascular B B
NF-A2 B I
invasion B I
silencer B B
element B I
and B O
lymphocytic B O
TNF-alpha B O
mRNA B O
infiltration B O
0 B B
MT-2 B I
Likewise B I
polymorphonuclear B B
leukocytes B I
was B O
not B O
NF-A1 B O
associated B O
with B O
transcriptional B B
silencer B I
element B I
markers B I
of B O
PPAR-alpha B B
and B O
#NAME? B O
disease B O
extension B O
HTLV-I-infected B O
human B O
T B O
cell B O
line B B
such B I
as B I
lymphocytes B I
TNM B I
NF-A2 B B
( B I
UICC B I
HLA B I
class B I
II B I
gene B I
classification B B
OBF-1 B I
mRNA B I
of B O
) B B
MT-2 B I
staging B I
and B O
lymphocytes B O
axillary B O
lymph B O
OCTA-binding B O
factor B O
NF-A1 B O
node B O
involvement B O
class B O
II B O
genes B O
or B O
with B O
cytokine B B
mRNA B I
estrogen B I
human B B
HeLa B I
cells B I
progesterone B I
peripheral B B
blood B I
leukocytes B I
and B O
glucocorticoid B O
OCTA-binding B O
protein B B
receptor B O
levels B O
class B O
II B O
genes B O
0 B O
However B B
adipophilin B I
mRNA B I
there B B
cultured B I
skin B B
fibroblasts B O
was B O
a B B
peripheral B I
blood B I
mononuclear B O
cells B O
significantly B O
positive B O
NF-A1 B O
association B O
between B O
class B O
II B O
genes B O
expression B O
and B O
CIITA B O
( B O
class B O
II B O
transactivator B O
) B O
transcripts B O
the B B
degree B I
T-cell B I
clones B I
of B O
lymphocytic B B
peripheral B O
blood B O
mononuclear B O
cells B O
infiltration B O
in B O
Ig B B
the B I
tumor B I
DRA B O
X B O
consensus B O
element B O
tissue B O
0 B O
Fas B O
ligand B O
( B O
FasL B O
) B O
mRNA B B
serum B O
levels B O
tegument-specific B O
CD4 B O
T-cell B O
clones B O
were B O
determined B O
mononuclear B O
cells B O
by B O
an B B
T B O
cell B O
activation-specific B O
enhancer B O
enzyme-linked B O
immunosorbent B O
X B O
box B O
assay B O
in B O
endogenous B B
germ-line B O
( B O
GL B O
) B O
alpha B O
transcripts B B
samples B O
from B O
U937 B B
cells B I
22 B I
of B O
peripheral B B
blood B O
mononuclear B O
cells B O
the B B
above B I
interleukin-2 B O
women B O
0 B O
functional B O
elements B B
Although B I
some B I
endogenous B I
GLalpha B I
transcripts B O
of B O
the B B
nonadherent B I
culture B O
highest B O
values B O
mononuclear B O
cells B O
had B O
been B O
IL-2 B O
obtained B O
in B O
immunoglobulin B B
heavy-chain B O
promoter B O
women B O
with B O
endogenous B B
GLalpha B O
transcripts B O
larger B O
( B O
U937 B O
cells B O
T4 B O
) B O
mononuclear B O
cells B O
primary B B
tumors B I
NFAT-1 B I
the B B
Immunoglobulin B I
heavy-chain B O
genes B O
authors B O
failed B O
MIP-1alpha B O
and B O
MIP-1beta B O
messenger B B
RNA B O
to B O
detect B O
B B O
cell B O
lines B O
any B O
statistical B O
natural B O
killer B O
( B O
NK B O
) B O
cell B O
relationship B O
between B O
NFAT-1 B O
expression B O
in B O
conserved B B
sequence B O
elements B O
the B B
tumor B I
ACAT-1 B O
mRNA B O
with B O
serum B B
B B O
cell B B
lines B O
levels B O
or B O
cytotoxic B B
T-cells B I
between B I
and B O
NFAT-1 B O
the B B
above B I
normal B I
cell-specific B I
promoter B I
histologic B I
interleukin-6 B B
laboratory B I
B B B
cell B I
hybridomas B I
and B O
clinical B O
NK B O
factors B O
0 B O
NFAT-1 B O
[ B O
Preliminary B O
conserved B O
sequence B O
elements B O
observation B O
of B O
NF-kappaB B B
and B I
cytokine B I
mRNA B I
level B I
levels B O
1G5 B O
cell B O
line B O
in B O
serum B B
NK B I
cell B I
of B O
normal B B
T B O
cell B O
antigen B O
receptor B O
childbearing-aged B O
and B O
octamer B O
element B O
pregnant B O
women B O
IFN-gamma B O
mRNA B O
] B O
In B O
U-373 B O
MG B O
cells B O
137 B O
cases B O
cytotoxic B O
effector B O
cell B O
of B O
childbearing-aged B B
thyroid B I
hormone B I
receptors B I
and B I
pregnant B I
heptamer B I
sequence B I
women B I
IL-6 B B
mRNA B I
levels B O
( B O
astrocytoma B O
cell B O
line B O
) B O
in B O
cytotoxic B B
effector B O
cell B O
serum B O
were B O
thyroid B O
hormone B O
receptors B O
measured B O
by B O
2 B O
or B O
14 B O
base B O
pairs B O
ELISA B O
0 B O
IL-6 B O
mRNA B O
The B B
level B I
Jurkat B I
cells B I
of B O
was B B
peripheral B O
mononuclear B O
cells B O
significantly B O
decreased B O
T3 B O
binding B O
sites B O
during B O
the B B
immunoglobulin B I
( B O
Ig B O
) B O
heavy B O
and B O
light B O
chain B O
genes B O
first B O
trimester B B
GATA-3 B I
mRNA B I
slightly B B
CD4-positive B I
lymphocyte B O
cell B O
line B O
higher B B
in B O
peripheral B B
lymphocytes B O
the B B
second B I
[ B O
125I B O
] B B
T3 B I
trimester B I
heavy B B
chain B I
enhancer B I
and B O
recovered B O
EBV-encoded B O
nuclear B O
RNA B O
to B O
normal B O
U-373 B O
MG B O
cells B O
in B O
the B B
B B I
cells B O
third B O
trimester B O
binding B O
sites B O
0 B O
The B B
Ig B O
genes B O
level B O
remained B O
EBER B O
lower B O
in B O
Jurkat B B
cells B O
29 B O
PIH B O
B B O
cells B O
women B O
but B O
[ B O
125I B O
] B O
T3 B O
appeared B O
higher B O
upstream B O
promoter B O
or B O
enhancer B O
element B O
in B O
overdue B B
EBV B O
nuclear B O
antigen B O
( B O
EBNA B O
) B O
-1 B O
mRNA B O
pregnancies B O
as B B
Jurkat B I
cells B O
compared B O
with B O
T B B
cell B O
the B B
normal B I
T3 B O
binding B O
sites B O
3rd B O
trimester B O
housekeeping B O
genes B O
range B O
0 B O
Latent B O
membrane B O
protein-1 B O
( B O
LMP-1 B O
) B O
mRNA B O
The B B
results B O
human B O
monocytic B O
leukemia B O
cell B O
lines B O
indicate B O
that B O
T B O
cell B O
there B B
is B O
T3 B O
binding B O
sites B O
a B B
relationship B I
histone B I
H2B B I
and B O
U B O
snRNA B O
genes B O
between B O
a B B
EBNA-2 B I
transcripts B I
change B O
in B O
monoblastic B B
ML-1 B O
cells B O
function B O
and B O
Lymphocyte B O
pregnancy B O
0 B O
thyroid B O
hormone B O
receptors B O
: B O
role B O
Ig B O
promoters B O
in B O
the B B
Latent B I
BHRF1 B I
transcripts B I
regulation B I
of B O
promonocytic B B
U-937 B O
cells B O
expression B O
0 B O
lymphocytes B O
Transcriptional B O
activation B O
human B O
T3 B O
receptors B O
of B O
the B B
TATA-box B I
like B B
bcl-2 B I
homologue B I
induction B I
of B O
promyelocytic B B
HL-60 B O
cells B O
the B B
and B O
lymphocytes B O
the B B
type B I
T-cell B O
specific B O
DNA-binding B O
factors B O
1 B O
human B O
octamer B O
sequence B O
immunodeficiency B O
virus B O
BCRF1 B O
transcripts B O
( B O
HIV-1 B O
monocytic B O
THP-1 B B
cells B I
) B I
B B B
cell B I
is B O
shown B O
T-lymphocyte B O
1 B O
to B O
be B O
IgH B O
enhancer B O
modulated B O
by B O
vIL-10 B O
and B O
bcl-2 B O
homologue B O
a B B
0 B I
HL-60 B I
cells B I
Mutation B I
of B O
peripheral B B
mononuclear B I
leukocytes B O
a B B
identified B I
silencer-DNA-protein B I
complex B O
in B O
the B B
IgH B I
enhancer B O
( B O
-206 B O
PPAR-gamma B O
to B O
-195 B O
HL-60 B O
cells B O
) B O
partially B O
human B O
peripheral B O
blood B O
lymphocytes B O
inhibits B O
both B O
DNA-binding B O
factors B O
mitogen- B O
and B O
human B O
immunodeficiency B O
virus B O
type B O
1 B O
promoter B O
HTLV-I B O
Tax-mediated B O
TCF-1 B O
mRNA B O
activation B O
of B O
THP-1 B B
cells B I
this B I
and B O
normal B O
human B O
mitogen-activated B O
T B O
lymphocytes B O
blocks B O
the B B
HLA B I
class B O
II B O
antigens B O
specific B O
binding B O
immunoglobulin B O
light B O
chain B O
genes B B
of B O
two B B
Id3 B O
transcripts B O
0 B O
These B O
VD3-treated B O
HL-60 B O
cells B O
and B O
THP-1 B O
cells B O
( B O
80 B O
human B O
natural B O
killer B O
( B O
NK B O
) B O
cell B O
to B O
90 B B
trans-acting B I
factors B I
and B O
50 B O
kappa B O
light B O
chain B O
enhancer B O
sequence B O
to B O
55 B B
RAR B I
alpha B I
RAR B B
gamma B I
RXR B B
beta B I
and B B
RXR B I
gamma B I
transcripts B O
kilodaltons B O
) B O
THP-1 B O
cells B O
similarly B O
interact B O
natural B O
killer B O
with B O
the B B
soluble B I
factors B O
functional B O
present B O
human B O
immunodeficiency B O
virus B O
type B O
I B O
promoter B O
in B O
the B B
RARbeta B I
mRNA B O
0 B O
These B O
VD3-treated B O
HL-60 B O
cells B O
data B O
suggest B O
human B O
peripheral B O
blood B O
mononuclear B O
( B O
PBM B O
) B O
cells B O
that B O
these B O
trans-acting B O
factor B O
have B O
a B B
upstream B I
NF-kappa B I
B-binding B O
site B O
role B O
in B O
TNFalpha B B
mRNA B O
the B B
coordinate B I
HL-60 B I
cells B I
regulation B I
of B O
PBM B O
cells B B
this B O
growth B O
class B O
II B O
antigens B O
factor-growth B O
factor B O
immunoglobulin B O
promoter B O
receptor B O
gene B O
MCP-1 B O
mRNA B O
system B O
that B O
THP-1 B B
cells B O
controls B O
proliferation B O
NK B O
cell B O
0 B O
Novel B O
NFX1.1 B O
region B O
within B O
upstream B O
element B O
the B B
is B O
messenger B O
RNA B O
responsible B O
for B O
THP-1 B B
cells B O
tissue B O
and B O
effector B O
cells B O
stage-specific B O
expression B O
NFX1.2 B O
of B O
in B O
promoters B B
0 B O
have B O
mRNA B O
been B B
shown B O
VD3-treated B O
HL-60 B O
cells B O
to B O
play B B
PBM B I
cells B O
a B B
role B I
NFX1.1 B I
in B O
lymphoid B B
modular B O
enhancer B O
element B O
tissue-specific B O
expression B O
intercellular B O
adhesion B O
molecule-1 B O
of B O
0 B B
HL-60 B O
cells B O
The B B
role B I
PBM B I
cells B I
of B O
these B B
NFX1.2 B O
factors B O
in B O
immunoglobulin B B
genes B O
differentiation B O
and B O
intercellular B O
adhesion B O
molecule-1 B O
stage-specific B O
expression B O
THP-1 B O
cells B O
of B O
these B B
NK B I
effectors B I
genes B I
is B I
glucocorticoid B I
receptor B I
however B B
upstream B I
regions B I
not B B
RAR-alpha B I
fully B O
understood B O
HL-60 B O
cells B O
0 B O
We B O
NK B O
have B O
used B O
glucocorticoid B O
receptor B O
a B B
model B I
heavy B I
and B I
light B I
chain B I
promoters B I
of B O
human B B
RAR-beta B O
lymphoid B O
neoplasia B O
VD3-treated B O
HL-60 B O
cells B O
and B O
THP-1 B O
cells B O
to B O
address B O
human B O
NK B O
cell B B
this B O
question B O
glucocorticoid B O
receptor B O
0 B O
Different B O
heavy B O
chain B O
enhancer B O
fragments B O
of B O
RXR-alpha B B
of B O
( B B
VD3-untreated B O
HL-60 B O
cells B O
) B O
were B O
human B O
T B O
cells B B
used B O
for B O
glucocorticoid B B
receptor B O
cell-free B O
in B O
kappa B B
light B O
chain B O
promoter B O
vitro B O
transcription B O
RXR-gamma B O
and B O
DNA B O
cultured B O
human B O
B-lymphoblastoid B O
cells B O
mobility B O
shift B O
lymphoid B O
and B O
non-lymphoid B O
cells B O
assays B O
0 B O
glucocorticoid B O
receptor B O
Previously B O
described B O
kappa B O
promoter B O
enhancement B O
of B O
IL-2 B B
in B O
vitro B B
B-LCL B O
transcription B O
that B O
circulating B O
mononuclear B O
lymphocytes B O
was B O
only B O
glucocorticoid B O
receptor B O
seen B O
with B O
DNA B B
nuclear B O
extracts B O
AP-1 B O
mRNA B B
derived B O
from B O
B-LCL B B
corresponding B O
to B O
B-lymphocytes B O
the B B
late B I
interferon-alpha B I
stages B I
of B O
DNA B B
differentiation B O
was B O
PPAR-gamma B O
mRNA B O
shown B O
to B O
class B O
II- B O
mutant B O
B-cell B O
lines B O
be B O
dependent B O
erythroid B O
cells B O
on B O
the B B
Estradiol B I
receptors B I
actions B I
of B O
immunoglobulin B B
VH B O
promoter B O
region B O
sequences B O
these B O
factor B O
eosinophil B O
mRNA B O
( B O
s B O
bare B O
lymphocyte B O
syndrome B O
group B O
II B O
cell B O
lines B O
) B O
on B O
CD4 B O
T B O
cells B O
the B B
DNA B I
interferon-alpha B O
region B O
within B O
human B O
and B O
murine B O
immunoglobulin B O
heavy B O
chain B O
variable B O
region B O
( B O
VH B O
) B O
genes B O
the B B
0 B I
NFATc B O
mRNA B O
This B O
region B O
RJ2.2.5 B O
is B O
located B O
infiltrating B O
CD4-bearing B O
T B O
cells B O
within B O
the B B
IFN-alpha B I
920 B O
bp B O
light B O
chain B O
variable B O
region B O
( B O
VL B O
) B O
genes B O
fragment B O
located B O
chemokine B O
mRNA B O
210 B O
bp B O
RM3 B B
upstream B O
from B O
HSV-specific B O
CD4 B O
T B O
cells B O
the B B
coding B I
estradiol B I
receptors B I
region B I
and B O
immunoglobulin B O
heavy B O
chain B O
transcriptional B O
enhancer B B
this B O
fragment B O
macrophage B O
inflammatory B O
protein B O
( B O
MIP B O
) B O
-2 B O
mRNA B O
represents B O
a B B
70Z/3 B I
pre-B B I
lymphocytes B O
possible B O
novel B O
T B O
cells B O
DNA B O
region B B
estradiol B I
receptors B I
which B B
immunoglobulin B I
genes B I
plays B O
a B B
MIP-1alpha B I
mRNA B I
role B O
in B O
macrophage B B
line B O
the B B
stage- B I
HSV-infected B I
cells B I
and B I
tissue-specific B I
estradiol B I
receptors B I
expression B I
of B O
Octamer-containing B B
fragments B O
0 B O
[ B O
MIP-1alpha B O
mRNA B O
Determination B O
of B O
macrophage B B
line B O
the B B
sensitivity B I
mononuclear B O
phagocytes B O
to B O
in B O
IFN-alpha B B
vitro B O
] B O
octamer-containing B O
fragments B O
A B O
modified B O
MIP-2 B O
mRNA B B
method B O
for B O
transfected B B
liver B O
cells B O
the B B
determination B I
Mononuclear B I
phagocytes B I
of B O
in B O
IFN-alpha B B
is B O
suggested B O
HTLV-I B O
LTR B O
0 B O
The B B
MIP-2 B O
mRNA B O
principal B O
distinction B O
HepG2 B O
human B O
hepatoma B O
cell B O
line B O
of B O
the B B
unstimulated B I
cells B O
method B O
is B O
estradiol B O
receptors B O
standardization B O
by B O
promoters B O
the B B
count B I
IRF-1 B O
mRNA B O
in B O
a B B
MVh2E1-9 B I
sample B I
( B O
Peripheral B O
blood B O
T B O
cells B O
and B O
monocytes B O
1 B O
mln B O
IFN-alpha B O
) B O
and B O
adenovirus B O
2 B B
major B O
late B B
gene B O
the B B
labeled B I
IRF-1 B O
mRNA B O
concentration B O
0 B O
HepG2 B O
cell B O
line B O
The B B
modification B O
normal B O
cells B O
saves B O
time B O
estradiol B O
receptors B O
and B O
money B O
mouse B B
beta-globin B I
gene B I
limits B B
IL-1beta-converting B I
enzyme B O
mRNA B O
the B B
range B I
HepG2 B I
cells B O
of B O
the B B
immune B I
cells B I
data B I
variations B I
estrogen B I
receptor B I
and B B
mouse B I
immunoglobulin B I
VH B O
gene B O
makes B O
use B B
AP-1 B I
mRNA B I
of B O
a B B
HepG2 B I
cell B I
lesser B I
volume B I
Peripheral B I
blood B I
monocytes B I
and B I
T B I
cells B I
of B O
blood B B
estrogen B O
receptor B O
0 B O
Examinations B O
LTR B O
of B O
70 B B
Human B O
p45 B O
mRNAs B O
children B O
aged B O
HepG2 B O
cell B B
4 B O
to B O
T B B
cells B O
15 B O
suffering B B
ER B O
from B O
the B B
LTR B I
nephrotic B I
form B I
aNF-E2 B I
of B O
glomerulonephritis B B
TNF B O
cytotoxicity B O
have B O
made B O
CD4 B B
it B O
possible B O
ER B O
to B O
distinguish B O
HTLV-I B B
LTR B I
two B I
groups B I
fNF-E2 B I
of B O
patients B B
liver B O
cell B O
lines B O
: B O
with B O
CD8 B B
relatively B I
high B I
glucocorticoid B I
receptors B I
values B I
of B O
transcriptional B B
control B O
elements B O
specific B O
binding B O
fNF-E2 B O
mRNA B O
X B O
= B O
HeLa B O
cells B O
6820.1 B O
+/- B O
monocytes B O
530 B O
( B O
glucocorticoid B O
receptors B O
n B O
= B O
immunoglobulin B B
genes B I
30 B I
fNF-E2 B B
p B I
= B I
HeLa B I
cells B I
0.95 B I
T B B
cells B I
t B O
= B O
GR B O
2.04 B O
) B B
immunoglobulin B I
genes B I
this B B
GM-CSF B I
mRNA B O
corresponding B O
to B O
HeLa B O
cells B O
a B B
clinical B I
Monocytes B I
form B I
of B O
GR B B
#NAME? B I
glomerulonephritis B I
immunoglobulin B I
gene B I
recombinants B I
and B B
Egr-1 B I
mRNA B O
with B O
relatively B B
HeLa B O
cells B O
low B O
values B O
T B O
cells B O
of B O
specific B B
GR B O
binding B O
X B O
cis-acting B O
transcriptional B O
regulatory B O
elements B O
= B O
1815.2 B O
Egr-1 B O
mRNA B O
+/- B O
302.8 B O
human B O
interleukin-2-dependent B O
T B O
lymphoblasts B O
( B O
n B O
B B O
cells B O
= B B
40 B I
GR B I
p B B
heavy B I
and B O
kappa B O
light-chain B O
genes B O
= B O
0.95 B B
Egr-1 B I
mRNA B I
t B B
human B I
T B O
cell B O
line B O
Jurkat B O
= B O
1.96 B O
T B B
lymphocytes B I
) B I
GR B B
that B I
corresponds B O
element B O
to B O
#NAME? B O
c-myc B O
mRNA B O
glomerulonephritis B O
0 B O
Jurkat B O
cells B O
Dynamic B O
studies B O
cultured B O
cells B O
have B O
not B O
GR B B
shown B O
any B O
heavy B O
and B O
kappa B O
light-chain B O
gene B O
promoters B O
statistically B O
significant B O
TNF-alpha B O
mRNA B O
changes B O
in B O
THP1 B B
monocytes B O
the B B
specific B I
primary B O
murine B O
bone B O
marrow B O
cells B O
binding B O
values B O
cytosolic B O
receptors B O
0 B O
These B O
viral B O
enhancers B O
results B O
permit B O
TNF-alpha B O
mRNA B O
regarding B O
the B B
human B I
THP1 B O
monocytes B O
specific B O
binding B O
granulocytic B O
colonies B B
value B I
as B I
GR B I
a B I
prognostic B I
regulatory B I
elements B O
criterion B O
in B O
jun B B
D B O
mRNA B O
the B B
assessment B I
THP1 B I
monocytes B I
of B O
therapy B B
peripheral B O
blood B O
neutrophil B O
O B B
this B I
GR B I
allows B O
a B B
DNA B I
sequences B I
wide B I
employment B I
mRNAs B O
of B O
the B B
THP1 B I
monocytes B O
described B O
method B O
T B O
and B O
natural B O
killer B O
cells B O
in B O
practical B B
GR B O
nephrology B O
0 B O
upstream B B
regions B O
from B O
stimulate B B
IL-6 B I
mRNA B I
transcription B I
of B O
cell B B
lines B O
the B B
in B O
lymphocyte B B
subsets B O
vitro B O
0 B O
GR B O
The B B
#NAME? B I
mouse B I
heavy B I
and B I
kappa B I
light-chain B I
gene B I
promoters B I
specificity B I
of B O
leukemia B B
inhibitory B O
factor B O
mRNA B O
the B B
( B I
B-cell B O
lines B O
) B O
heavy-chain B O
T B O
lymphocyte B B
subsets B I
and B I
light-chain B I
ubiquitous B I
and B O
lymphoid-cell-specific B O
octamer B O
transcription B O
factors B O
promoters B O
is B O
mouse B O
heavy-chain B O
gene B O
enhancer B O
mediated B O
by B O
cytokine B B
mRNA B I
an B I
non-B-cell B B
or B I
plasma B I
cell B I
lines B I
ATGCAAAT B I
NK B B
cells B I
that B O
is B O
OTF-1 B O
also B O
a B B
transcriptional B I
elements B I
functional B O
component B O
cytokine B O
genes B O
T B O
cell B O
clone B O
variant B O
of B O
other B B
T-cell B I
and B I
natural B I
killer B I
( B I
T/NK B I
) B I
populations B I
such B B
OTF-2 B I
as B I
snRNA B I
IgNF-A B I
and B O
histone B O
resting B O
cloned B O
T B O
lymphocyte B O
H2B B O
promoters B O
CD8+ B O
CD28+ B O
population B O
0 B O
Two B O
homo- B O
or B O
heterodimeric B O
complexes B O
that B O
bind B O
beta-like B O
globin B O
locus B O
specifically B O
and B O
L2 B O
with B O
high B B
T/NK B O
subsets B O
affinity B O
to B O
OTF B O
the B B
have B I
beta-globin B O
promoter B B
been B O
identified B O
L2 B O
cells B O
0 B B
is B I
CD4+ B I
CD8+ B B
and B I
CD56+ B I
cell B I
populations B O
present B O
in B O
OTFs B B
a B I
variety B I
beta-like B I
globin B I
cluster B I
of B O
cell B B
L2 B I
and B I
L2 B I
variant B I
cells B I
types B I
T/NK-cell B B
subsets B I
whereas B O
the B B
lymphoid B I
specific B O
octamer B O
binding B O
protein B O
presence B O
of B O
HSV B B
DNA B I
is B O
essentially B O
L2 B O
cells B O
confined B O
to B O
T/NK-cell B O
leading B B
OTF-2B B I
to B O
the B B
genes B I
UL49 B I
and B O
UL50 B O
hypothesis B O
that B O
L2 B O
variant B O
cells B O
activates B O
cell-type-specific B O
T/NK B O
cells B O
transcription B O
of B O
octamer B B
binding B O
proteins B O
the B B
and B I
UL21 B O
mediates B O
the B B
L2 B I
cells B O
other B O
responses B O
AML B O
of B O
the B B
OTF-1 B I
0 B O
Extracts B O
HIV-1 B O
enhancer B O
of B O
the B B
LPS-stimulated B I
human B I
blood B I
monocytes B I
T B B
cells B I
contain B I
high B I
transcription B I
factors B I
levels B I
of B O
NF-kappa B B
B B I
sites B I
and B O
specifically B O
CML B O
cells B O
transcribe B O
0 B O
T B O
cells B O
In B O
contrast B O
lymphoid B O
cell B O
specific B O
octamer B B
binding B I
protein B I
extracts B B
chloramphenicol B I
acetyltransferase B O
( B O
CAT B O
) B B
reporter B O
from B O
transcribed B O
thymidine B O
kinase B O
( B O
tk B O
) B O
inducible B O
human B O
cell B O
lines B O
the B B
poorly B I
T B I
lymphocytes B I
0 B I
Surprisingly B I
OTF-2A B I
addition B B
cDNA B I
of B O
either B B
TK6i-G3 B I
and B O
G9 B O
tk B O
heterozygous B O
cell B O
lines B O
affinity-enriched B O
NF-A2 B O
T B O
cells B O
or B O
NF-A1 B O
B B O
cell B O
specific B O
octamer B O
binding B O
protein B O
to B O
either B B
exons B I
1��8�� B O
a B B
HeLa B I
human B I
cell B O
lines B O
extract B O
or B O
human B B
glial B I
cells B I
and B I
lymphocytes B O
a B B
partially B I
OTF-2B B I
purified B O
reaction B O
exon B O
5 B O
system B O
specifically B O
PMA B B
induced B O
HL60 B O
cells B O
stimulates B O
the B B
lymphocyte B I
0 B O
This B O
OTF-2B B O
suggests B O
that B O
exon B O
7 B O
the B B
constitutive B I
TF-1 B O
cells B O
can B O
activate B O
lymphocyte B O
transcription B O
of B O
OTF-2A B B
the B I
and B I
FasL B I
promoter B I
that B O
#NAME? B O
erythroleukemia B O
cell B O
line B O
transcription B O
of B O
human B O
tumors B B
this B O
promoter B O
novel B B
octamer B I
factor B I
at B B
NF-kappa B I
B B I
and B O
AP-1 B O
binding B O
sites B B
least B O
in B O
TF-1 B B
cells B I
vitro B I
mature B B
peripheral B I
blood-derived B I
myeloid B I
and B I
lymphoid B I
cells B I
is B O
partially B O
OTF-2B B O
due B O
to B O
human B B
immunodeficiency B O
virus B O
type B O
1 B O
long B O
terminal B O
repeat B O
a B B
quantitative B I
TF-1 B I
cells B O
difference B O
in B O
bone B B
marrow B O
haemopoietic B O
progenitors B O
the B B
amount B I
60 B I
kd B I
species B I
OTF-2A B I
of B O
0 B B
HIV-1 B O
LTR B O
Because B O
can B O
TF-1 B O
cells B O
stimulate B O
transcription B B
ringed B I
sideroblasts B I
the B B
interleukin B I
2 B I
inability B I
of B O
HIV-1 B B
LTR-dependent B O
gene B B
this B O
factor B O
TF-1 B O
cells B O
to B O
activate B O
highly B O
purified B O
immature B O
CD34+ B O
38- B O
and B O
committed B O
CD34+ B O
38+ B O
marrow-derived B O
progenitors B O
in B O
vivo B B
inhibitory B O
protein B O
the B O
to B O
luciferase B O
gene B O
the B B
same B I
HL-60 B I
cells B I
degree B I
as B I
CD16+ B I
14- B O
granulocytes B O
the B B
probably B I
interleukin B I
2 B I
reflects B I
a B I
wild-type B I
but B B
not B I
the B I
kappaB-mutated B I
HIV-1 B B
LTR B I
region B O
difference B O
in B O
HL-60 B B
cells B O
the B B
context B I
CD14+ B I
monocytes B O
of B O
the B B
IL B I
2 B O
in B O
these B B
Human B O
immunodeficiency B O
virus B O
type B O
1 B O
long B O
terminal B B
repeat B O
two B O
types B O
HL-60 B O
cell B O
of B O
0 B B
CD3+ B I
T B I
and B I
CD19+ B I
B B I
lymphocytes B I
Identification B I
of B O
hormone B O
a B B
putative B I
long B I
terminal B I
repeat B I
regulator B I
of B O
Tax-expressing B B
JPX-9 B O
cells B O
0 B O
Molecules B O
granulocytes B O
involved B O
in B O
IL B B
2 B O
the B B
antigen B I
LTR B O
receptor-dependent B O
regulation B O
Jurkat B O
T B O
cells B O
of B O
were B B
monocytes B O
investigated B O
with B O
IL B B
2 B O
the B B
use B I
LTR-directed B I
gene B I
of B O
functional B B
ovarian B O
cancer B O
cell B O
lines B O
sequences B O
of B O
CD34+ B B
progenitor B O
cells B O
the B B
of B I
IL B O
2 B O
receptors B O
( B O
) B O
LTRs B O
0 B O
One B O
purified B O
human B O
erythroid B O
colony-forming B O
cells B O
of B O
these B B
CD3+ B O
T B O
lymphocytes B O
sequences B O
forms B O
glucocorticoid B O
receptor B O
a B B
protein B I
LTRs B I
complex B I
ECFC B B
specifically B B
CD19+ B I
B B O
cells B O
with B O
nuclear B B
hormones B I
extracts B I
of B O
LAI B B
LTR B O
activated B O
0 B O
human B O
Jurkat B O
T-cells B O
This B O
complex B O
CD3+ B O
T B O
cells B O
appeared B B
10 B O
inhibitory B O
protein B O
to B O
25 B O
455-bp B O
U3 B O
region B O
minutes B O
before B O
human B O
Jurkat B O
T B O
cells B O
the B B
activation B I
monoclonal B I
B B I
and B I
polyclonal B I
T B I
lymphocytes B O
of B O
the B B
IL B I
2 B O
0 B O
Studies B O
LTRs B O
with B O
inhibitors B B
Jurkat B I
T-cells B I
of B O
protein B B
progenitor B O
synthesis B O
indicated B O
IL B O
2 B O
that B O
the B B
LAI B I
LTR B I
time B I
of B O
Raji B B
B B I
cell B I
lymphoma B I
synthesis B I
of B O
myeloid B B
and B O
B-lymphoid B O
lineages B O
the B B
activator B I
IL B I
2 B I
receptor B O
of B O
the B B
LTRs B I
in B O
corresponds B B
CHO B O
cells B O
to B O
the B B
mature B I
myeloid B I
cells B I
time B I
of B I
hormones B I
appearance B I
of B I
LTRs B I
0 B I
Jurkat B B
T B I
cells B O
or B O
a B B
committed B I
marrow B I
progenitors B I
very B I
similar B I
IL B I
2 B I
protein B I
LAI B B
LTR B I
bound B O
functional B O
neuroblastoma B O
( B O
NB B O
) B O
cell B O
lines B O
sequences B O
of B O
human B B
lymphocytes B O
the B B
( B I
human B I
immunoglobulin-enhancer-binding B I
protein B I
) B I
of B O
LTR B B
sequence B O
the B B
human B I
NB B O
cell B O
lines B O
immunodeficiency B O
virus B O
peripheral B O
blood B O
T B O
and B O
B B O
cells B O
type B O
1 B O
NF-kappa B O
B B O
O B O
the B B
cis-acting B I
sites B I
of B O
this B B
NB B O
cell B O
lines B O
virus B O
is B O
peripheral B O
lymphocytes B O
known B O
to B O
enhancer-binding B O
factor B O
NF-kappa B O
B B O
be B O
stimulated B O
U3 B O
region B O
during B O
early B O
NB B O
cell B O
lines B O
activation B O
0 B O
T B O
and B O
B B O
cells B B
The B O
for B O
NF-kappa B O
B B B
this B O
complex B O
LTR B O
activated B O
a B B
clonogenic B I
cells B I
linked B O
promoter B O
T B O
cells B O
after B O
transfection B O
51-kDa B O
polypeptide B O
into B O
but B O
LEF-1 B O
and B O
distal B O
NF-kappaB B O
transcription B O
factor B O
binding B O
sites B O
not B O
other B O
human B O
acute B O
nonlymphocytic B O
leukemia B O
cell B O
lines B O
HL-60 B O
and B O
KG-1 B O
cell B O
types B O
Human B O
white B O
blood B O
cells B O
0 B O
These B O
NF-kappa B O
B B O
characteristics B O
suggest B O
HIV-1 B O
LTR B O
that B O
transmits B O
Mononuclear B O
or B O
clonogenic B O
cells B O
signals B O
initiated B O
human B O
white B O
blood B O
cells B O
at B O
the B B
glucocorticoid B I
receptor B O
0 B O
Characterization B O
LTR B O
sequence B O
of B O
in B O
clonogenic B B
HL-60 B O
and B O
KG-1 B O
cells B O
0 B O
Although B O
class B O
II+ B O
mature B O
B-cells B O
putatively B O
identified B O
glucocorticoid B O
receptor B O
more B B
than B I
mammalian B I
sex-determining B I
gene B I
Sry B I
10 B I
years B O
mononuclear B O
cell B B
preparations B I
ago B I
class B B
II- B I
plasma B O
B-cells B O
in B O
human B B
glucocorticoid B O
receptor B O
tissues B O
remain B O
MRP14 B O
gene B O
poorly B O
characterized B O
labeled B O
cells B O
0 B O
As B O
class B O
II+ B O
mature B O
B-cells B O
a B B
first B I
glucocorticoid B I
receptor B O
step B O
towards B O
transcription B O
factor B O
binding B O
motifs B O
understanding B O
the B B
CML B I
cells B I
mechanism B I
of B O
antibody-secreting B B
cells B O
thyroid B O
hormone B O
human B O
lymphoid-specific B O
octamer-binding B O
protein B O
action B O
in B O
CCAAT/enhancer B B
binding B O
protein B O
( B O
C/EBP B O
) B O
#NAME? B O
motif B B
man B I
we B I
1 B I
25- B B
( B I
OH B O
) B O
2D3 B O
receptor-positive B O
T47D B O
have B O
characterized B O
B B B
cells B O
in B O
nuclei B B
OTF-2 B O
of B O
the B B
upstream B I
region B I
0 B B
T47D B I
In B O
whole B O
gp39-expressing B O
T B O
cells B O
cell B O
experiments B O
ubiquitous B O
and B O
B B O
cell-specific B O
octamer-binding B O
proteins B O
at B O
37 B O
MRP14 B O
gene B O
degrees B B
C B I
T47D B I
nuclear B B
human B I
Wurzburg B I
T B I
cells B I
binding B I
of B O
B B B
cell B O
factor B O
was B O
saturable B O
luciferase B O
reporter B O
DNAs B O
( B O
Kd B O
CML B O
34 B O
+/- B O
rat B O
thymocytes B O
6 B O
pmol/l B O
B B O
cell-specific B O
factor B B
) B I
and B I
MRP14 B I
gene B I
of B O
finite B B
CML B O
cells B O
capacity B O
( B O
affected B O
blood B O
cell B O
lineages B O
approximately B O
equal B O
affinity-purified B O
ubiquitous B O
factor B O
to B O
350 B O
X-chromosome B O
sites/cell B O
) B O
mouse B O
and B O
human B O
lymphoid B O
cell B O
lines B O
0 B O
The B B
lymphoid B O
cells B O
were B O
extracted B O
B B O
cell-specific B O
octamer-binding B B
factor B I
from B O
a B B
X-chromosome B I
nuclear B I
pellet B I
mouse B I
and B O
human B O
lymphoid B O
cell B O
lines B O
by B O
treatment B O
human B O
umbilical B O
vein B O
endothelial B O
cells B O
with B O
0.4 B B
B B O
cell-specific B O
transcription B O
factor B O
mol/l B O
KCl B O
major B O
histocompatibility B O
complex B O
class B O
II B O
gene B O
and B O
sonication B O
Cell B O
lines B O
0 B O
Separation B O
endothelial B O
cells B O
of B O
bound B B
ubiquitous B I
and B O
B B O
cell-specific B O
octamer-binding B B
factors B O
from B O
free B O
CCAAT-box B O
DNA B O
motifs B O
in B O
the B B
dexamethasone-sensitive B I
cell B O
lines B B
extracts B O
was B O
adherent B O
cells B O
achieved B O
using B O
glucocorticoid-receptor B O
complex B O
the B B
calcium B I
class B O
II B O
genes B O
phosphate B O
matrix B O
dexamethasone-resistant B B
cell B I
lines B I
hydroxyapatite B B
adherent B I
leukocytes B O
at B O
a B B
glucocorticoid B I
receptors B I
concentration B I
of B O
abnormal B B
gene B O
0.3 B O
ml B O
pokeweed B B
mitogen-stimulated B I
cultures B I
of B O
a B B
endothelial B I
cells B I
150 B O
g/l B O
GR B O
slurry B O
0 B O
CAG B O
repeat B O
Rectilinear B O
Scatchard B O
CLL B O
cells B O
plots B O
were B O
rolling B O
cells B O
obtained B O
only B O
GR B O
when B O
the B B
first B I
exon B O
hydroxyapatite B O
was B O
human B O
CLL B O
cells B O
washed B O
with B O
leukocytes B O
a B B
buffer B I
GR B I
complex B O
containing B O
0.5 B O
androgen B O
receptor B B
gene B O
% B O
Triton B B
high B O
receptor B O
cell B O
lines B O
X-100 B O
0 B O
IL-1beta-stimulated B O
endothelial B O
cells B O
Under B O
these B O
GR B O
complexes B O
conditions B O
in B O
active B B
X B O
chromosome B O
the B B
nuclear B I
low-receptor B O
cell B O
lines B O
extracts B O
were B O
leukocytes B O
present B O
at B O
GR B O
complex B O
a B B
concentration B I
paternal B I
and B I
maternal B I
alleles B I
of B O
22.4 B B
low-receptor B O
lines B O
+/- B O
8.6 B O
leukocytes B O
fmol/mg B O
protein B O
Granulocyte-macrophage B O
colony-stimulating B O
factor B O
and B O
showed B O
dominant B O
negative B O
( B O
DN B O
) B O
Ikaros B O
mutation B O
an B O
affinity B O
cultured B O
human B O
lymphoblasts B O
of B O
( B B
IL-1beta-treated B I
endothelial B I
cells B I
Kd B I
multilineage B B
growth B I
factor B O
room B O
temperature B O
Ikaros B O
mutations B O
) B O
140 B O
human B O
lymphoblast B O
cell B O
lines B O
+/- B B
10 B O
leukocytes B O
pmol/l B O
0 B O
granulocyte-macrophage B O
colony-stimulating B O
factor B O
The B B
same B O
multiple B O
B B O
lineage B O
genes B O
assay B O
system B B
LICR-LON-HMy2 B O
was B B
used B O
endothelial B O
cells B O
to B O
determine B O
GM-CSF B O
the B B
hierarchy B I
many B I
B B I
lineage B I
genes B I
of B O
affinities B B
HMy2 B I
cells B I
for B O
a B B
human B I
umbilical B I
vein B I
endothelial B I
cells B I
range B I
of B O
GM-CSF B B
natural B I
and B O
B B O
lineage-associated B O
genes B O
synthetic B O
analogues B O
GM4672A B O
cells B O
0 B O
Calling B O
adhering B O
leukocytes B O
T3 B B
100 B I
1 B I
25 B B
( B I
OH B I
) B I
2D3 B I
cellular B I
receptors B I
the B B
3.6 B I
kilobases B I
order B I
of B O
HMy2 B B
and B O
GM4672A B O
cells B O
potencies B O
observed B O
hemopoietic B O
stem B B
cell B O
was B O
: B B
GM-CSF B I
Triac B I
c-myc B B
500 B I
O B I
HMy2 B I
cell B I
3 B I
B B B
lymphocytes B I
5-diiodo-3'-isopropylthyronine B I
interleukin B B
2 B I
89 B I
O B I
bcl-6 B I
T4 B I
GM4672A B B
cells B I
32 B O
O B O
B B O
lineage B B
cells B I
3 B I
cellular B B
1 B I
25 B B
( B I
OH B O
) B O
2D3 B O
receptors B O
5-dimethyl-3'isopropylthyronine B O
2 B O
tumor-suppressor B O
genes B O
O B O
3 B B
Dex-treated B I
cells B I
5-T2 B B
human B I
T B I
lymphocytes B I
0.7 B B
nuclear B I
receptors B I
rT3 B B
IL-8 B I
gene B I
reporter B I
constructs B I
0.4 B B
Dex-treated B I
GM4672A B O
cells B O
O B O
3'5'-T2 B O
human B O
peripheral B O
blood B B
mononuclear B I
cells B I
less B B
nuclear B I
receptors B I
than B I
0.01 B I
NF-kappaB B I
and B O
3'NF-IL-6 B O
DNA B O
binding B O
sites B O
0 B O
These B O
GM4672A B O
cells B O
results B O
suggest B O
PBMCs B O
that B O
the B B
thyroid B O
hormone B O
receptors B O
present B O
in B O
IL-8 B B
gene B O
nuclei B O
and B O
HMy2 B O
cells B O
extracts B O
thereof B O
PBMCs B O
are B O
0 B O
monoclonal B O
anti-human B O
corticosteroid-binding B O
globulin B O
( B O
CBG B O
) B O
antibody B O
These B O
cells B O
5'NF-IL-6 B O
binding B O
site B O
may B O
be B O
HMy2 B O
and B O
GM4672A B O
cells B O
a B B
useful B I
epithelial B I
cells B O
tool B O
to B O
phosphodiesterase B O
increase B O
our B B
IL-8 B I
gene B I
understanding B I
of B O
GM4672A B B
cells B I
Definition B I
of B O
T B O
cells B O
that B O
interact B O
adenylate B O
cyclase B O
with B O
a B B
serum B I
response B I
region B O
in B O
the B B
human B I
mononuclear B O
leukocytes B O
0 B O
Analysis B O
human B O
peripheral B O
blood-derived B O
T B O
lymphoblasts B O
of B O
the B B
phosphodiesterase B I
region B O
3 B O
tissue B O
factor B O
promoter B O
' B O
to B O
lymphocyte B O
subpopulations B O
the B B
( B I
T B O
cells B O
encoding B O
regulatory B O
anti-CBG B O
antibody B O
protein B O
) B O
Egr-1 B O
motifs B O
led B O
to B O
lymphocyte B O
populations B O
the B B
definition B I
peripheral B I
blood B I
mononuclear B I
cells B I
of B O
a B B
glucocorticoid B I
receptors B I
that B O
inhibits B O
chimeric B O
plasmids B O
expression B O
in B O
CML B B
certain B O
but B O
PBMC B O
not B O
in B O
CBG B B
or B O
0 B O
tissue B O
factor B O
promoter B O
Functional B O
activity B O
CLL B O
in B O
vivo B B
T B O
cells B O
was B O
associated B O
cell-type-specific B O
nuclear B O
proteins B O
with B O
the B B
intact B I
Sp1 B I
sites B I
presence B I
of B O
AML B O
a B B
specific B I
LCL-stimulated B I
cells B O
in B O
electrophoretic B B
immunoglobulin B O
mobility B O
shift B O
Egr-1 B O
sites B O
assays B O
with B O
ALL B B
extracts B O
0 B O
IL-2-dependent B O
T B O
cells B O
Formation B O
of B O
nuclear B O
protein B B
this B O
complex B O
IL-6 B O
gene B O
was B O
selectively B O
CML B O
inhibited B O
by B O
HTLV-I-producing B O
cells B O
the B B
region B I
HTLV-I B O
viral B O
proteins B O
in B O
containing B B
IL-2 B O
gene B O
a B B
0 B I
AML B I
CLL B B
and B I
ALL B I
peripheral B I
leucocytes B O
We B O
discuss B O
normal B O
resting B O
T B O
cells B O
the B B
possibility B I
viral B O
proteins B O
that B O
may B B
IL-10 B I
IFN-gamma B B
and B I
TNF-alpha B I
genes B I
coregulate B O
HIV-1 B O
K562 B O
cells B O
and B O
Rpt-1 B O
microglia B O
gene B O
expression B O
nuclear B O
factor B O
through B O
a B B
c-jun B I
c-fos B B
and B I
NFATc1 B I
( B I
NFATc B O
) B O
genes B O
common B O
0 B O
dexamethasone-treated B O
macrophages B O
Congenital B O
immunodeficiencies B O
microglia B O
associated B O
with B O
Trans-acting B B
factors B I
absence B I
of B O
gp34 B B
gene B O
on B O
result B B
macrophages B O
from B O
distinct B O
primary B O
rat B O
microglia B O
mutations B O
in B O
human B B
B-cell B O
nuclear B O
factor B O
0 B O
Coordinate B O
gp34 B O
gene B O
regulation B O
of B O
leukemic B B
T-cell B O
populations B O
expression B O
during B O
microglia B B
development B I
and B I
IgNF-A B I
coinduction B I
of B O
gp34 B B
gene B O
by B O
suggests B O
hydroxyurea-treated B O
cells B O
that B O
common B O
microglia B O
( B O
s B O
glucocorticoid B O
receptors B O
) B O
control B O
NF-kappaB-like B B
elements B I
expression B I
of B O
human B B
clonal B O
monocytic B O
cell B O
line B O
these B O
genes B O
human B O
monocyte B O
0 B O
In B O
glucocorticoid B O
receptor B O
derived B O
from B O
regulatory B B
region B I
two B O
independent B O
CM-SM B O
class B O
II-deficient B O
human B O
monocyte-derived B O
macrophages B O
bare B O
lymphocyte B O
cytosolic B O
hormone-receptor-complexes B O
syndrome B O
patients B B
NF-kappaB-like B I
elements B I
we B B
CM-SM B I
observed B O
a B B
MAC B I
drastic B I
decrease B O
unactivated B O
receptor B O
complexes B O
in B O
transcription B B
NF-kappaB-like B O
element B O
1 B O
rates B O
of B O
clonal B O
line B O
the B B
0 B I
freshly B O
isolated B O
monocytes B O
When B O
these B O
aldosterone B O
receptor B O
cell B O
lines B O
native B B
promoter B I
are B I
fused B I
CM-SM B I
are B B
MO B I
reexpressed B I
erythroid B B
Kruppel-like B I
factor B O
indicating B O
that B O
NF-kappaB-like B O
element B O
1 B O
immunodeficiencies B O
in B O
CM-SM B B
bare B O
lymphocyte B O
MO B O
syndrome B O
patients B O
EKLF B O
are B O
the B B
NF-kappaB B I
elements B I
result B I
of B O
cell B B
population B I
two B O
distinct B O
MAC B O
mutations B O
0 B O
histone B O
acetyltransferases B O
Further B O
studies B O
NF-kappaB-like B O
elements B O
show B O
that B O
untreated B B
cells B O
genes B O
governing B O
MO B O
the B B
expression B I
Erythroid B I
Kruppel-like B I
factor B I
of B O
fall B B
NF-kappaB-like B O
elements B O
into B O
at B B
DEX-treated B I
cells B I
least B I
three B I
MO B O
complementation B O
groups B O
EKLF B B
O B I
two B I
cognate B I
and B I
noncognate B I
core B I
promoters B I
of B O
these B B
malignant B O
clones B O
were B O
previously B O
MAC B O
unidentified B O
in B O
red B B
cell-specific B O
transcriptional B O
activator B O
generated B O
in B O
gp34 B B
gene B O
vitro B O
0 B O
ALL B O
cells B O
In B O
addition B B
MO-derived B I
dendritic B I
cells B I
we B B
EKLF B I
report B O
the B B
paired B I
box B I
containing B I
gene B I
identification B I
of B O
CLL B B
cells B I
two B I
discrete B I
MAC B I
complexes B I
positive-acting B B
factor B I
and B I
PAX-5 B B
that B I
bind B O
PHA-stimulated B O
cell B O
cultures B O
to B O
the B B
MO-derived B I
dendritic B O
cells B O
0 B O
Though B O
EKLF B O
the B B
mutation B I
PAX-5 B O
in B O
at B B
CML B I
cells B I
least B I
one B I
MAC B O
generated B O
in B O
acetylated B B
transcription B O
factor B O
vitro B O
( B O
mammalian B O
interferon-gamma B O
activation B O
site B O
) B O
affects B O
ANLL B O
cells B O
products B O
functioning B O
MO B O
via B O
interaction B O
CBP B O
with B O
the B B
interferon-gamma B I
activation B I
site B I
sequence B I
clear B B
peanut-positive B I
and B O
peanut-negative B O
human B O
thymocyte B O
subpopulations B O
alterations B O
in B O
dendritic B B
cells B O
either B O
or B O
p300 B O
are B O
not B O
CRE B O
sequences B O
found B O
in B O
peanut-negative B B
thymocyte B O
subpopulation B O
any B O
of B O
B B B
cells B O
the B B
0 B I
P/CAF B O
In B O
vivo B O
nm23 B O
gene B O
responsiveness B O
to B O
peanut-positive B O
glucocorticoid B O
correlated B O
mantle B O
zone B O
B B O
cells B O
with B O
content B B
histone B O
acetyltransferases B B
in B O
in B B
nm23 B O
gene B O
normal B O
humans B O
peanut-negative B O
subset B O
0 B O
Dexamethasone B O
follicular B O
center B O
B B O
cells B O
loading B O
tests B O
CBP B O
( B O
0.1 B O
thymidine B O
kinase B O
locus B O
mg B B
dexamethasone/kg B I
peanut-positive B I
iv B B
Monocytoid B I
B B O
cells B O
) B O
were B O
p300 B O
performed B O
in B O
tk B B
allele B O
18 B O
normal B O
human B O
B-lymphoblastoid B O
cell B O
line B O
males B O
to B O
plasma B O
cells B O
evaluate B O
the B B
P/CAF B I
individual B O
responsiveness B O
promoter B O
element B O
to B O
glucocorticoid B O
IM-9 B O
0 B O
There B O
extrafollicular B O
large B O
transformed B O
B B O
cells B O
were B O
inter-individual B O
EKLF B O
differences B O
in B O
BCL-6 B B
gene B O
increase B O
in B O
human B B
T-cell B O
leukemic B O
cell B B
line B I
count B I
mantle B B
cells B I
decrease B O
in B O
CBP B B
count B I
Ig B B
genes B I
and B O
increase B O
CEM-C7 B B
in B O
plasma B B
MCLs B O
free B O
fatty B O
p300 B B
acids B O
levels B O
Immunoglobulin B O
( B O
Ig B O
) B O
genes B O
after B O
dexamethasone B O
glucocorticoid B O
receptor-deficient B O
cell B O
line B O
injection B O
0 B O
MCLs B O
In B B
addition B I
P/CAF B I
there B B
non-Ig B I
promoters B I
was B O
a B B
ICR-27 B I
significant B I
correlation B O
nonmalignant B O
mantle B O
cells B O
between B O
the B B
EKLF B I
maximum B I
increase B I
c-MYC B I
S14 B B
or B B
alpha-fetoprotein B I
( B O
AFP B O
) B O
genes B B
in B O
and B B
human B O
malignant B O
thymus B O
derived B O
T B O
cell B O
line B O
the B B
maximum B I
tumor B O
cells B O
decrease B O
in B O
EKLF B B
( B O
r B O
Ig B O
genes B O
= B O
0.7514 B B
MOLT B I
3 B I
p B B
B-cell B I
lineage B O
less B O
than B O
tissue-specific B O
transcription B O
factor B O
0.0003 B O
) B O
BCL6 B O
gene B O
0 B O
Simultaneous B O
MOLT B O
3 B O
cells B O
measurements B O
of B O
B-cell B B
subsets B O
content B O
by B O
EKLF B O
whole-cell B O
assay B O
huMIP-1 B O
alpha B O
gene B O
revealed B O
that B O
OKT8 B O
cells B O
content B O
in B O
large-cell B B
lymphomas B O
linearly B O
correlated B O
herpes B O
simplex B O
virus B O
type B O
2 B O
tegument B O
proteins B O
with B O
that B O
proto-oncogene B B
in B O
the B B
Ia-restricted B I
T B O
cell B O
hybridomas B O
corresponding B O
( B O
follicular B O
lymphomas B O
r B O
= B O
tegument B B
protein B I
0.9482 B I
t B B
( B I
14 B O
O B O
19 B O
) B O
p B O
less B O
T B O
cell B O
hybridomas B O
than B O
0.0001 B O
channel B O
catfish B O
lymphoid B O
cells B O
) B O
0 B O
VP22 B O
There B O
were B O
human B O
immunodeficiency B O
virus-type B O
1 B O
( B O
HIV-1 B O
) B O
kappaB-TATA-luceriferase B O
reporter B O
plasmid B O
also B O
significant B O
Ia-bearing B O
stimulator B O
cells B O
correlations B O
between B O
endotoxin-stimulated B O
human B O
blood B O
monocytes B O
the B B
maximum B I
viral B O
dUTPase B O
increase B O
in B O
kappaB-containing B B
genes B O
and B O
content B O
T B O
hybridoma B O
in B O
( B B
human B O
monocyte B O
r B O
= B O
T-cell B B
antigens B I
0.7239 B I
kappaB B B
enhancer B I
p B O
less B O
TA3 B O
stimulator B O
cell B O
than B B
0.0007 B I
monocytes B I
) B I
epitopes B B
and B I
between B O
c-myb B O
promoter B O
the B B
maximum B I
TA3 B O
cells B O
decrease B O
in B O
monocytes B B
and B O
content B O
VP22 B B
in B O
( B B
c-myb B O
kappaB-TATA-luceriferase B O
reporter B O
plasmid B O
r B O
= B O
T B O
cell B B
hybridomas B I
0.7703 B I
peripheral B B
blood B I
mononuclear B O
cells B O
p B O
less B O
tegument B O
protein B O
than B O
0.0002 B O
kappaB-containing B O
genes B O
) B O
0 B O
glucocorticoid-sensitive B O
and B O
#NAME? B O
variants B O
These B O
results B O
bone B O
marrow B O
mononuclear B O
cells B O
suggest B O
that B O
VP16 B O
individual B O
differences B O
c-myb B O
are B O
preserved B O
human B O
leukemic B O
cell B O
line B O
both B O
in B O
bone B B
marrow B O
cells B O
glucocorticoid B O
responsiveness B O
tegument B O
protein B O
and B O
in B O
IL-2 B B
gene B O
content B O
in B O
CEM B B
C7 B O
in B O
normal B B
Proliferated B O
blastic B O
cells B O
humans B O
0 B O
VP22 B O
Estradiol B O
receptors B O
IL-2 B O
gene B O
in B O
the B B
glucocorticoid-sensitive B I
cells B I
cytosol B I
of B O
human B B
cells B O
in B O
hepatitis B B
herpes B O
simplex B O
tegument B O
proteins B O
B B O
virus B O
TR3/nur77 B O
gene B O
carriers B O
treated B O
glucocorticoid-sensitive B O
cells B O
with B O
0 B B
human B O
cells B O
in B O
the B B
Fibrinogen B I
cytosol B I
of B O
NOR-1 B B
promoter B O
and B O
the B B
glucocorticoid-resistant B I
cell B I
line B I
effects B I
of B O
B B B
cells B O
( B O
) B O
NF-kappa B O
B B O
transcription B O
factors B O
on B O
were B O
luciferase B O
reporter B O
gene B O
studied B O
in B O
glucocorticoid-sensitive B B
cell B O
line B O
asymptomatic B O
hepatitis B O
B B O
lymphocytes B O
B B O
virus B O
NF-kappa B O
B B O
transcription B O
factors B O
( B O
HBV B O
NGFI-B B O
( B O
rat B O
homolog B O
of B O
TR3/Nur77 B B
) B O
response B O
element B O
) B B
carriers B I
C7 B I
patients B B
memory B I
B B O
cells B O
with B O
chronic B B
fibrinogen-binding B O
integrins B O
hepatitis B O
B B O
NBRE B O
and B O
normal B O
leukemic B O
cell B O
lines B O
controls B O
0 B O
B B O
cells B O
The B B
level B I
CD11b/CD18 B O
of B O
in B O
TR3/nur77 B B
promoter B O
sequence B O
the B B
cytosol B I
Human B O
lymphoid B O
cell B O
lines B B
of B O
was B B
memory B O
B B O
cells B O
significantly B O
lower B O
CD11c/CD18 B O
in B O
asymptomatic B B
NBRE B I
HBV B I
carriers B I
lymphoblastoid B I
leukaemia B B
and B I
lymphoma B I
lines B I
and B I
patients B I
CD45RA+ B I
and B O
CD45RO+ B O
T B O
cells B O
with B O
chronic B B
fibrinogen B O
hepatitis B O
B B O
heat B O
shock B B
promoter-reporter B I
construct B I
compared B B
human B I
lymphoid B O
cell B O
lines B O
to B O
normal B O
CD45RA+ B O
cells B O
controls B O
0 B O
NF-kappa B O
B B O
This B O
low B O
proximal B O
promoters B O
level B O
of B O
HLCL B B
cytosol B O
in B O
CD45RA+ B B
( B O
naive B O
) B O
and B O
CD45RO+ B O
( B O
memory/effector B O
) B O
T B O
cells B O
patients B O
with B O
fibrinogen B B
chronic B O
hepatitis B O
distal B O
elements B B
B B O
was B O
lymphoblastoid B O
increased B O
by B O
CD45RA+ B O
cells B O
the B B
administration B I
Fibrinogen B I
of B O
0 B B
cytokine B I
gene B I
loci B I
In B I
addition B I
lymphoma B I
when B B
CD45RO+ B I
cells B I
from B O
patients B O
AP-1 B O
with B O
chronic B B
cytokine B O
genes B O
hepatitis B O
B B O
leukaemia B O
were B O
incubated B O
CD45RA+ B O
cells B O
with B O
in B B
SP1 B I
vitro B I
inflammation B B
genes B I
the B I
level B I
leukaemia B I
and B I
lymphoblastoid B I
lines B I
of B O
cytosol B B
CD45RA+ B O
cells B O
also B O
increased B O
cAMP B O
response B O
element-binding B O
protein B O
( B O
CREB B O
) B O
factors B O
by B O
increasing B O
DNA B O
response B O
elements B O
the B B
concentration B I
HLCL B I
of B O
0 B B
CD45RO+ B O
cells B O
We B O
previously B O
mAbs B O
reported B O
that B O
BCL-6 B O
5 B O
' B O
noncoding B O
regions B O
the B B
response B I
hemopoietic B I
lineage B O
of B O
to B O
CD45RA+ B B
and B O
CD45RO+ B O
cells B O
estrogen B O
is B O
CD18 B O
impaired B O
in B O
inflammatory B B
genes B O
HBV B O
carriers B O
p65-expressing B B
Jurkat B I
cells B I
and B B
CD45RA+ B I
cells B I
our B O
present B O
CD11b B O
results B O
suggested B O
cytokine B O
and B O
chemokine B O
genes B O
that B O
this B O
B7-1-costimulated B O
cells B O
may B O
be B O
CD45RA+ B O
and B O
CD45RO+ B O
T B O
lymphocytes B O
due B O
to B O
fibrinogen B O
the B B
low B I
cytokine B I
and B I
chemokine B I
genes B I
level B I
of B O
myeloid B B
cell B O
lines B O
in B O
the B B
Lymphoma B I
cells B I
cytosol B I
of B O
NF-kappa B B
B B O
0 B O
Association B O
inflammatory B O
genes B O
of B O
increased B B
promonocytic B O
U937 B O
( B O
U9-IIIB B O
) B O
and B O
myeloblastic B O
PLB-985 B O
( B O
PLB-IIIB B O
) B O
cells B O
lytic B O
effector B O
monocytes B O
cell B O
function B O
fibrinogen B O
with B O
high B B
bcl-6 B I
proto-oncogene B I
levels B O
in B O
parental B B
U937 B O
tumor-bearing B O
patients B O
T-cells B O
with B O
breast B B
fibrinogen B O
cancer B O
0 B O
bcl-6 B O
Tumor-bearing B O
patients B O
PLB-985 B O
cells B O
with B O
breast B B
transformed B O
B-cells B O
cancer B O
were B O
fibrinogen-derived B O
proteins B B
assayed B O
for B O
bcl-6 B B
promoter B O
region B O
their B B
activity B I
U937 B I
and B O
U9-IIIB B O
cells B B
and B O
for B O
monocytes B O
the B B
function B I
CD11b/CD18 B I
of B I
activated B I
bcl-6 B I
as B B
U9-IIIB B I
and B O
PLB-IIIB B O
cells B O
assessed B O
by B O
B-cells B O
lectin-dependent B O
cellular B O
transcriptional B O
regulatory B O
factors B O
cytotoxicity B O
( B O
mouse B O
E2A B O
gene B O
LDCC B O
) B O
Jurkat B O
T B O
cells B O
0 B O
Tumor-bearing B O
T-cells B O
patients B O
with B O
NF-kappa B B
B B O
breast B O
cancer B O
human B O
HEB B O
cDNA B O
had B O
a B B
U9-IIIB B I
cells B I
significant B O
increase B O
proliferating B O
human B O
erythroid B O
precursors B O
in B O
activity B B
hormone B O
binding B O
domain B O
and B O
in B O
mammalian B B
E2A B I
HEB B B
and B B
E2-2 B I
genes B I
LDCC B I
U9-IIIB B B
cells B I
as B I
compared B I
early B O
burst-forming B O
unit-erythroid B O
( B O
BFU-E B O
) B O
#NAME? B O
erythroid B O
precursors B O
with B O
healthy B B
functional B O
receptor B O
proteins B O
control B O
individuals B O
E2A B O
0 B O
Although B O
Jurkat B O
lymphocyte B O
cell B O
line B O
the B B
enhanced B I
hematopoietic B I
cells B I
activity B I
and B O
wild B O
type B O
ER B O
LDCC B O
were B O
HEB B O
closely B O
associated B O
Jurkat B O
T-cells B O
with B O
high B B
erythroid B I
cells B I
levels B O
( B O
hormone B O
binding B O
domain B O
variants B O
greater B O
than B O
E2-2 B O
31 B O
fmol/mg B O
Jurkat B O
T B O
cells B O
) B O
of B O
granulocytic B B
cells B O
( B O
) B O
Fas B O
ligand B O
content B O
in B O
E2A B B
the B I
primary B I
primary B O
human B O
peripheral B O
blood B O
mononuclear B B
cells B I
tumor B I
granulocytic B B
cells B I
no B O
other B O
NF-kappa B O
B B O
clinical B O
or B O
HEB B O
histologic B O
correlation B O
lymphoma B O
between B O
the B B
naive B I
and B O
memory B O
human B O
T B O
lymphocytes B O
increase B O
in B O
AP-1 B B
either B O
parameter B O
E2-2 B O
of B O
function B B
EBV-associated B I
lymphomas B I
could B O
be B O
naive B O
and B O
memory B O
human B O
T B O
lymphocytes B O
found B O
0 B O
Fas B B
ligand B I
Thus B I
E2A B B
levels B I
greater B O
B B O
lineage B O
cells B O
than B O
31 B O
purified B O
peripheral B O
blood B O
T B O
lymphocytes B O
fmol/mg B O
might B O
FasL B O
be B O
associated B O
E12 B O
and B O
E47 B O
exons B O
with B O
increased B B
HS-72 B O
mouse B O
hybridoma B O
cells B O
function B O
in B O
adherent B B
cells B O
tumor-bearing B O
patients B O
transcription B O
factors B O
NF-kappa B O
B B O
and B O
AP-1 B O
with B O
breast B B
E12 B I
and B O
E47 B O
exons B O
cancer B O
0 B O
HS-72 B O
cells B O
Properties B O
of B O
peripheral B B
blood B O
human B O
T B O
( B O
PB-T B O
) B O
cells B B
in B O
from B B
FasL B O
patients B O
with B O
human B B
HEB B O
cDNA B O
familial B O
cortisol B O
HS-72 B O
cells B O
resistance B O
0 B O
CD28/CD3-costimulated B O
T B O
cells B O
In B O
a B B
nondegradable B I
mutant B I
previous B I
report B I
E2A B I
gene B I
of B O
two B B
HS-72 B O
cells B O
patients B O
with B O
CD4+ B B
familial B O
glucocorticoid B O
I B O
kappa B O
B B O
resistance B O
due B O
HEB B O
to B O
reduced B B
MonoMac6 B I
cells B I
numbers B I
of B O
CD4- B B
( B I
) B I
FasL B I
we B B
endogenous B I
E2A B I
promoter B O
have B O
shown B O
MB-treated B B
THP-1 B O
cells B O
decreased B O
numbers B O
CD45RO+ B O
of B O
in B O
p65 B B
Rel B O
and B O
but B O
E2A B B
normal B O
affinity B O
monocytic B O
U937 B O
cells B O
of B O
in B O
CD45RO- B B
both B O
patients B O
Fos/Jun B O
0 B O
In B O
E2A B B
this B I
study B I
U937 B I
cells B I
from B B
PB-T B I
cells B I
these B I
patients B I
NF-kappa B I
B B I
one B B
HEB B I
patient B O
's B B
U937 B I
cells B I
son B I
and B I
CD45RO+ B I
and B I
CD4+ B I
subsets B I
daughter B I
AP-1 B B
and B I
normal B O
E12 B B
subjects B O
were B O
U937 B O
cells B O
transformed B O
with B O
PB-T B B
cells B O
Epstein-Barr B O
virus B O
FasL B O
0 B O
Reduced B O
E47 B O
numbers B O
and B O
cardial B O
or B O
eye B B
cell B O
lineages B O
normal B O
affinity B O
human B O
T-lymphotropic B O
virus B O
type B O
1-infected B O
cells B O
of B O
were B B
granulocyte-colony-stimulating B O
factor B O
found B O
in B O
HEB B B
the B I
from B I
MM B O
cell B O
lines B O
both B O
patients B O
HTLV-1-infected B O
cells B O
while B O
the B B
granulocyte-colony-stimulating B I
factor B I
son B I
and B O
human B O
IL-2 B O
promoter B O
daughter B O
had B O
melanoma B O
cell B O
lines B O
normal B O
numbers B O
mammalian B B
cells B I
and B I
affinity B I
G-CSF B I
of B O
0 B B
luciferase B O
reporter B O
gene B O
constructs B O
The B B
thermal B O
melanoma B O
cell B O
lines B O
stability B O
of B O
body B B
wall B I
muscle B I
cells B I
and B I
thermal B I
G-CSF B I
activation B I
of B O
IL-2 B B
promoter B O
in B O
both B B
melanoma B O
cell B O
lines B O
patients B O
were B O
T B O
lymphocytes B O
found B O
to B O
multiple B O
signaling B B
proteins B O
be B O
normal B O
IL-2 B O
promoter-enhancer B O
region B O
0 B O
Although B O
melanoma B O
cell B O
lines B O
the B B
percentages B I
macrophage B I
infiltrate B I
of B O
nuclear B B
murine B O
G-CSF B O
receptor B O
bound B O
were B O
CD28 B O
response B O
element B O
similar B B
in B O
Jurkat B B
T B O
both B O
patients B O
ovarian B O
cancer B O
cells B O
and B O
normal B O
oligomerizing B B
receptor B I
chains B I
controls B I
DR3 B B
gene B I
the B I
absolute B I
Jurkat B I
cells B I
amounts B I
of B O
macrophages B B
nuclear B O
bound B O
PML/RAR B O
alpha B O
of B O
the B B
human B I
chromosome B O
1p36 B O
patients B O
were B O
Jurkat B O
cells B O
about B B
one-half B I
lamina B O
propria B O
mononuclear B O
cells B O
that B O
of B O
PML/RAR B B
alpha B O
normal B O
controls B O
human B O
DR3 B O
gene B O
0 B O
These B O
lymphocytic B O
and B O
monocytic B O
lineages B O
abnormal B O
properties B O
lamina B O
propria B O
mononuclear B O
cells B O
of B O
( B B
AML1/ETO B O
reduced B O
numbers B O
DR3 B O
gene B O
locus B O
of B O
) B B
CD4 B O
( B O
+ B O
) B O
CD8 B O
( B O
+ B O
) B O
thymocyte B O
line B O
were B O
preserved B O
peripheral B O
blood B O
mononuclear B O
cells B O
in B O
the B B
CD4 B I
from B O
the B B
human B I
chromosome B O
band B O
1p36.2-p36.3 B O
patients B O
0 B O
CD4 B O
( B O
+ B O
) B O
CD8 B O
( B O
+ B O
) B O
thymocyte B O
line B O
Octamer B O
transcription B O
peripheral B O
blood B O
mononuclear B O
cells B O
factors B O
1 B O
CD8 B O
and B O
2 B O
DR3 B O
gene B O
each B O
bind B O
OX40-transfected B O
ACH-2 B B
cell B I
line B I
ACH-2/OX40 B B
to B I
two B O
PBMCs B O
different B O
in B O
CD56 B B
the B I
0 B I
DR3 B O
and B O
the B B
DR3L B I
sequences B I
contain B I
two B I
gp34-transfected B I
mouse B I
cell B I
line B I
SV-T2/gp34 B B
5 B I
' B O
monocytes B O
to B O
the B B
NF-kappaB B I
site B I
of B O
chromosome B B
transcription B O
initiation B O
ACH-2/OX40 B O
cells B O
: B O
the B B
PBMCs B I
octamer B O
ATGCAAAT B O
CD4 B O
and B O
the B B
nuclear B I
chromatin B O
heptamer B O
CTCATGA B O
CXCR4-using B O
T-cell-line-tropic B O
0 B O
Both B O
germinal B B
center-related B O
B B O
cells B O
of B O
these B B
protein B O
tyrosine B O
kinase B O
( B O
s B O
) B O
elements B O
are B O
gene B O
required B O
for B O
MT-2 B B
cells B O
function B O
0 B O
GC B O
B B O
cells B O
The B B
present B O
protein B O
kinase B O
A B O
study B O
demonstrates B O
pX B O
region B O
that B O
both B O
SV-T2/gp34 B O
cells B O
the B B
( B I
mature B I
B B I
cells B I
and B I
protein B B
kinase B I
C B O
respectively B O
) B O
IL-2 B O
receptor B O
gene B O
interact B O
specifically B O
THP-1 B O
cells B O
with B O
each B B
GC B I
B B I
cells B O
of B O
the B B
transcription B I
factor B I
NF-kappaB B I
two B I
chromatin B B
forming B I
either B O
Mo-7e B O
cells B O
0 B O
This B O
GC B O
B B O
cells B O
was B O
surprising B B
endogenous B I
TNF-alpha B I
since B B
chromosomes B I
14 B I
and B O
17 B O
the B B
heptamer B I
Mo-7e B I
and B I
HEL B I
cells B I
and B O
octamer B O
endothelial B O
cells B O
sequence B O
motifs B O
transcription B O
factor B O
bear B O
no B O
chromosome B O
14 B O
obvious B O
similarity B O
YT B O
cells B O
to B O
each B O
human B O
endothelial B O
cells B O
other B O
0 B O
activating B O
transcription B O
factor B O
Binding B O
of B O
CD28RE B B
either B O
factor B O
human B O
NK B O
cell B O
line B O
to B O
the B B
ECV B I
cells B O
occurred B O
independently B O
cAMP B O
response B O
element B O
binding B O
0 B O
However B B
IL-2 B I
promoter B I
interaction B B
B B I
cell B O
lineage B O
with B O
the B B
ECV B I
cells B O
appeared B O
to B O
ATF B O
require B O
the B B
IL-2 B I
promoter B I
presence B I
of B O
T B B
cell B O
lineage B O
an B O
intact B O
PMA-activated B O
untreated B O
cells B O
octamer B O
motif B B
CREB B I
and B O
occurred B O
IL-2 B O
promoter B O
with B O
a B B
Jurkat B I
T B I
cells B I
spacing B I
of B O
ECV B B
cells B O
either B O
between B O
HMG B O
box B O
containing B O
transcription B O
factors B O
the B B
two B I
activation B I
protein-1 B I
response B I
element B I
elements B I
CH12.LX.4933 B B
( B I
mu B O
( B O
+ B O
) B O
) B O
B B O
lymphoma B O
cells B O
suggesting B O
coordinate B O
germinal B O
center B O
( B O
GC B O
) B O
B B O
and B O
T B O
cells B O
binding B O
resulting B O
HMG B B
box B O
from B O
protein-protein B O
IL-2 B O
promoter B O
interactions B O
0 B O
lymphoma B O
cell B O
line B O
The B B
degeneracy B O
immature B O
thymic B O
T B O
lymphocytes B O
in B O
sequences B B
transcription B O
factors B O
recognized B O
by B O
nuclear B O
factor B O
kappabeta B O
reporter B O
construct B O
the B B
may B I
human B O
T-cell B O
line B O
Kit B O
225 B O
cells B O
be B O
important B O
splenic B O
T B O
lymphocytes B O
in B O
widening B B
HMG B O
box B O
proteins B O
the B B
range B I
IL-2 B O
promoter B O
over B O
which B O
resting B O
Kit B O
225 B O
cells B O
gene B O
expression B O
neutrophils B O
can B O
be B O
Sox-4 B O
modulated B O
and B O
CD28 B O
response B O
element B O
( B O
CD28RE B O
) B O
#NAME? B O
reporters B O
in B O
establishing B B
Jurkat B O
T B O
cells B O
cell B O
type B O
splenic B O
leukocytes B O
specificity B O
0 B O
TCF-1 B O
Identification B O
of B O
IL-2 B B
promoter- B I
and B I
CD28RE-driven B I
reporter B I
constructs B O
a B B
novel B I
COS-7 B I
cells B O
( B O
) B O
T B O
and B O
B B O
lymphocytes B O
by B O
proteolytic B O
LEF-1 B O
clipping B O
bandshift B O
CD28RE B O
assay B O
( B O
CD8+ B O
T B O
cell B O
clones B O
PCBA B O
) B O
immune B O
cells B O
and B O
tissues B O
0 B O
The B B
TCF/LEF B O
proteins B O
octamer B O
sequence B O
upstream B O
nuclear B O
factor B O
kappabeta-binding B O
site B O
ATGCAAAT B O
is B O
hematopoietic B O
stem B B
cell B I
line B I
A-6 B B
found B I
in B O
T B B
cells B O
the B B
promoters B I
TCF/LEF B I
of B O
and B O
IL-2 B O
promoter B O
in B O
the B B
hematopoietic B I
stem B I
cell B I
line B I
A-6 B B
and B I
is B O
T B O
cells B O
a B B
major B I
HMG B I
box B I
proteins B I
determinant B I
of B O
CD28RE B O
the B B
cell B I
A-6 B O
hematopoietic B O
stem B O
cell B O
line B O
type B O
specific B O
lymphocytes B O
expression B O
of B O
C/EBP B B
alpha B I
and B O
#NAME? B O
in B O
0 B B
IL-2 B O
promoter B O
An B O
apparent B O
Jurkat B O
T B O
cells B O
paradox B O
is B O
monocytes B O
that B O
the B B
MRP14 B O
myeloid B O
calcium B O
binding B O
protein B O
same B O
sequence B O
CD28RE B O
serves B O
as B B
acute B I
myeloid B O
leukemias B O
an B B
in B O
B B B
lymphopoiesis B O
a B B
variety B I
myeloid B I
calcium B I
binding B I
protein B I
of B O
such B B
IL-2 B O
promoter B O
as B O
the B B
M4Eo B I
0 B I
The B I
T B I
cells B I
differential B I
usage B I
MRP14 B I
of B O
this B B
vav B O
regulatory B O
sequence B O
EBV-positive B O
cell B O
lines B O
motif B O
is B O
T B O
cells B O
thought B O
to B O
MRP14 B O
be B O
mediated B O
vav B O
by B O
different B O
EBV-positive B O
cell B O
lines B O
species B O
of B O
antigen-presenting B B
cells B O
0 B O
One B O
nuclear B O
protein B O
( B O
s B O
) B O
species B O
of B O
vav B B
100 B I
kd B I
B95.8 B I
designated B B
APC B I
is B B
C/EBP B I
alpha B O
present B O
in B O
NF-ATc1 B B
and B O
egr-1 B O
genes B O
all B B
cell B I
Raji B I
types B I
and B O
co-stimulate B O
human B O
T B O
cells B O
may B O
exert B O
nucleoprotein B O
complex B O
its B O
activating B O
E-selectin B O
gene B O
function B O
only B O
Jiyoye B O
when B O
it B B
CD4+ B O
T B O
cells B O
can B O
interact B O
C/EBP B O
beta B O
with B O
additional B B
tetracycline-responsive B O
promoter B O
adjacent B O
0 B O
cell B O
lines B O
The B B
of B O
T B B
cells B O
60 B O
kd B O
nuclear B O
factor B O
( B O
) B O
DNA B O
termini B O
specifically B O
stimulates B O
cell B O
lines B O
which B B
consist B O
CD86+ B O
APC B O
essentially B O
of B O
anti-C/EBP B B
delta B I
antibody B O
a B B
and B I
DNA-ends B I
an B I
upstream B I
cell B I
line B I
cells B I
of B O
it B B
human B O
neuroblastoma B O
0 B O
Here B O
C/EBP B O
alpha B O
and B O
#NAME? B O
we B B
present B O
lineage-specific B O
genes B B
evidence B O
for B O
lymphoid B B
and B O
myeloid B O
cell B O
lineages B O
yet B O
another B O
thymocytes B O
of B O
75 B B
C/EBP B O
motif B O
kd B O
( B O
myeloid-specific B O
genes B O
) B O
0 B O
human B O
bronchial B O
epithelial B O
cell B O
line B O
BEAS-2B B O
From B O
several B B
lymphocytes B I
findings B I
C/EBP B B
alpha B I
including B O
the B B
proto-oncogene B I
absence B I
of B O
Jurkat B B
T B O
cells B O
( B O
but B O
mammalian B O
cells B O
not B O
) B O
C/EBP B B
beta B I
from B O
a B B
pX B I
open B I
reading B O
frame B O
I B O
that B O
can B O
breast B O
cancer B O
cell B O
lines B O
not B O
respond B O
normal B O
and B O
malignant B O
human B O
myeloid B O
progenitors B O
to B O
the B B
C/EBP B I
motif B I
we B B
human B I
immunodeficiency B O
virus B O
type B O
1-based B O
retroviral B O
vector B O
propose B O
a B B
murine B I
fetal B I
liver B O
cell B O
line B O
AFT024 B O
role B O
of B O
CFU-GM B O
the B B
in B O
C/EBP B B
motif B O
the B B
long B I
local B O
DNA B O
structure B O
range B O
activation B O
HD-derived B O
cell B O
lines B O
by B O
the B B
normal B I
cells B O
0 B O
We B O
C/EBP B O
motif B O
have B O
used B O
EBV-encoded B B
latent B O
membrane B O
protein B O
1 B O
( B O
LMP1 B O
) B O
oncogene B O
the B B
proteolytic B I
human B O
mast B O
cell B O
line B O
HMC-1 B O
clipping B O
bandshift B O
normal B O
cells B O
assay B O
( B O
C/EBP B O
beta B O
PCBA B O
) B O
EBV B O
latency B O
genes B O
technique B O
to B O
HL-60 B O
cells B O
distinguish B O
the B B
Malignant B I
cells B O
three B O
different B O
C/EBP B O
beta B O
forms B O
found B O
TNF-alpha B O
gene B O
in B O
0 B B
U-937 B O
This B O
analysis B O
granulocyte/macrophage B O
progenitors B O
indicates B O
that B O
CYP11A B O
the B B
75 B I
p21 B O
( B O
CIP1/WAF1 B O
) B O
promoter B O
kd-species B O
is B O
KU812 B O
cells B O
closely B O
related B O
CFU-GM B O
to B O
the B B
CYP17 B I
0 B O
Inhibition B O
p21 B O
( B O
CIP1/WAF1 B O
) B O
promoter B O
of B O
#NAME? B B
HMC-1 B I
cells B I
proliferation B I
of B O
malignant B B
progenitors B O
by B O
glucocorticoids B O
HSD11L B O
0 B O
Possible B O
29-base B O
pair B O
( B O
b B O
) B O
region B O
involvement B O
of B O
HL60 B B
cell B O
an B O
0 B O
CML B O
progenitors B O
The B B
ability B I
11beta-hydroxysteroid B I
dehydrogenase B I
I B I
of B O
glucocorticoids B B
TATA B O
box B O
to B O
inhibit B O
HL60 B O
cell B O
( B O
) B O
CFU-GM B O
#NAME? B O
proliferation B O
HSD17B1 B B
in B O
two B B
29-b B O
region B O
has B O
been B O
Jurkat B O
T B O
cells B O
studied B O
0 B O
peripheral B O
mononuclear B O
cells B O
A B O
complete B O
17beta-hydroxysteroid B O
dehydrogenase B O
type B O
I B O
inhibition B O
of B O
29-b B B
region B O
DNA B O
synthesis B O
Jurkat B O
T B O
cells B O
by B O
dexamethasone B O
leukemic B O
blasts B O
( B O
Dx B O
SRD5A1 B O
) B O
could B O
PPAR-alpha/GAL4 B O
luciferase B O
reporter B O
be B O
observed B O
Jurkat B O
cells B O
when B O
of B O
leukemic B B
cells B O
were B O
either B O
5alpha-reductase B O
I B B
incubated B O
for B O
PPAR-gamma/GAL4 B B
constructs B O
6 B O
h B O
EBV-positive B O
cell B O
lines B O
with B O
the B B
leukemic B I
cells B O
prior B O
to B O
CYP11B B O
the B B
addition B I
PPAR B I
response B I
element B I
luciferase B I
reporter B I
of B O
or B B
EBV-negative B I
cell B O
lines B O
treated B O
simultaneously B O
human B O
chronic B O
myeloid B O
leukemia B O
cells B O
with B O
Dx B B
HSD3B1 B I
and B O
a B B
IL-12 B I
p40 B I
gene B O
low B O
concentration B O
Jurkat B O
mutants B O
of B O
0 B B
intact B O
cells B O
No B O
significant B O
HSD3B2 B O
reduction B O
in B O
IL-12 B B
p40 B O
gene B O
the B B
number B I
p56 B O
( B O
lck B O
) B O
#NAME? B O
Jurkat B O
mutants B O
and B O
affinity B O
Exponentially B O
growing B O
cells B B
of B O
was B B
3beta-hydroxysteroid B O
dehydrogenase B O
I B O
and B O
II B O
seen B O
after B O
IL-12 B O
p40 B O
gene B O
6 B O
h B O
cancer B O
cell B O
lines B O
incubation B O
with B O
lymphoid B B
cells B O
Dx B O
0 B O
CYP19 B O
The B B
order B I
IL-12 B I
p35 B I
gene B I
of B I
potency B I
NB4 B I
a B B
human B I
promyelocytic B I
leukemia B O
cell B O
line B O
observed B O
with B O
human B B
leukemic B O
cells B O
the B B
different B I
HSD11K B O
steroids B O
indicated B O
IFN-regulatory B O
factor-1 B O
gene B O
that B O
this B O
NB4 B O
cells B O
inhibitory B O
effect B B
lymphoblasts B O
was B O
mediated B O
17-hydroxysteroid B O
dehydrogenase B O
through B O
binding B O
IL-12 B O
p40 B O
gene B O
to B O
a B B
NB4 B I
cells B I
specific B O
0 B O
normal B O
peripheral B O
blood B O
lymphocytes B O
The B B
action B I
5alpha-reductase B I
of B O
these B B
octamer B O
site B O
DNA B O
possibly B O
involves B O
NB4 B O
cells B O
the B B
synthesis B I
cell B I
specimen B O
of B O
an B B
pterin B O
carbinolamine B O
dehydratase/dimerization B O
cofactor B O
( B O
s B O
Bcl-2 B B
transgene B I
) B I
Jurkat B B
T B I
cells B O
since B O
the B B
ALL B I
cells B I
presence B I
of B O
HNF1 B B
cycloheximide B O
during B O
tensin B O
homologue B O
the B B
incubation B I
Jurkat B O
cells B O
with B O
Dx B B
human B O
mononuclear B O
leukocytes B O
prevented B O
the B B
Pterin B I
carbinolamine B I
dehydratase/dimerization B I
cofactor B I
inhibition B I
of B O
chromosome B B
10 B I
DNA B O
synthesis B O
Jurkat B O
T B O
cells B O
0 B O
Furthermore B O
human B B
mononuclear B I
leukocytes B I
supernatant B B
HNF1 B I
from B O
Dx-treated B O
GC B O
box B O
contained B O
a B B
myeloid B I
cell B I
line B O
nondialyzable B O
factor B O
human B O
mononuclear B O
leukocytes B O
which B B
inhibited B O
PCD/DCoH B O
DNA B O
synthesis B O
minimal B B
promoter B I
and B I
cell B I
human B I
and B I
murine B I
B-cell B I
lines B I
growth B I
of B O
lymphocyte B B
induced B O
by B O
pterin B O
4alpha-carbinolamine B O
dehydratase B O
0 B O
Blocking B O
consensus-binding B O
sites B O
of B O
synthesis B B
ovalbumin B O
expressing B O
tumour B O
cell B O
line B O
and B O
formation B O
immunoglobulin B O
secreting B O
cells B O
have B O
been B O
cofactor B B
tetrahydrobiopterin B O
proposed B O
as B B
minimal B I
promoters B I
one B I
of B O
E.G7-OVA B O
the B B
major B I
T B I
lymphocytes B I
mechanisms B I
of B O
HNF1 B B
glucocorticoid-induced B I
immunosuppression B I
galectins B I
-1 B I
-2 B B
and B B
-3 B I
0 B I
Our B O
murine B O
myeloid B O
cell B O
line B O
32D B O
results B O
indicate B O
lymphocyte B O
that B O
these B O
HNF1 B O
may B O
also B O
GC B O
box B O
affect B O
proliferation B O
32D B O
cells B O
by B O
inhibiting B O
chronic B O
lymphocytic B O
leukemia B O
cells B O
activity B O
0 B O
dual B O
functional B O
protein B B
Identification B I
and B I
Oct B I
site B I
purification B I
of B O
cultured B B
human B O
mesangial B O
cells B O
a B B
( B I
Human B I
chronic B O
lymphocytic B O
leukemia B O
( B O
CLL B O
) B O
cells B O
) B O
that B O
NF-Y B O
transcription B O
factor B O
complex B O
activates B O
transcription B O
GATA B O
and B O
EoTF B B
sites B I
from B O
a B B
CHMC B I
in B I
vitro B B
prothymocytes B O
0 B O
The B B
transcription B I
factor B I
which B B
consensus B I
GC B O
box B O
is B O
found B O
CHMC B O
only B B
in B O
immunoactivated B B
T-lymphocytes B O
cells B O
that B O
NF-Y B B
transcribe B I
Oct B B
site B I
has B O
been B O
CHMC B B
purified B O
from B O
peripheral B O
blood B O
lymphocytes B O
nuclear B O
extracts B O
heterotrimeric B O
NF-Y B O
complex B O
of B O
( B B
gal-1 B O
) B O
by B O
FCS-stimulated B O
CHMC B O
sequence-specific B O
DNA B O
thymocytes B O
affinity B O
chromatography B O
NF-Y B O
complex B O
0 B O
The B B
GC B O
box B O
purified B O
has B O
CHMC B O
been B O
identified B O
CLL B B
cells B I
as B I
a B I
anion B I
exchangers B I
by B O
UV-crosslinking B O
consensus B O
AML B O
site B O
analysis B O
0 B O
DT40 B O
B B O
cells B O
`` B O
Footprint B B
dead B O
cells B O
'' B O
and B O
trimeric B O
complex B O
methylation-interference B O
analyses B O
Inr B O
sequence B O
have B O
shown B O
Hodgkin B B
disease B O
cell B O
lines B O
that B O
purified B O
rat B O
or B O
murine B O
lymphocytes B O
has B O
a B B
NF-Y B I
binding B I
activity B O
gal-10 B O
promoter B B
specific B O
for B O
cutaneous B B
T B O
cell B O
lymphoma B O
( B O
CTCL B O
) B O
cell B O
lines B O
the B B
0 B I
cells B O
The B B
purified B O
NF-YA B O
factor B O
activated B O
MHC B O
class B O
II B O
genes B O
in B O
vitro B B
CTCL B O
cell B O
lines B B
HuT-78 B I
and B I
HH B I
transcription B I
of B O
mononuclear B B
leukocytes B O
the B B
by B I
NF-YB B O
: B O
C B O
binding B O
to B O
class B O
II B O
transactivator B O
an B O
binding B O
CTCL B O
cell B O
line B O
in B O
depression B B
Percoll-separated B O
control B O
monocytes B O
: B O
normal B O
subunit B O
fractions B O
values B O
following B O
B B O
cell-specific B O
promoter B O
recovery B O
0 B O
CTCL B O
cell B O
lines B O
The B B
number B I
monocytes B I
of B O
sites B B
MPC11 B O
plasma B O
B-cell B O
derived B O
NF-Y B O
A B O
: B O
B B O
: B O
C B O
complex B B
in B O
and B B
HLA-DR B O
plasma B O
cortisol B O
CTCL B O
cell B O
lines B O
concentrations B O
were B O
circulating B O
human B O
mononuclear B O
leukocytes B O
measured B O
in B O
NF-Y-associated B B
factors B O
20 B O
patients B O
HLA-DP B O
who B B
had B O
human B O
Jurkat B O
T-cell B O
line B B
recovered B O
from B O
mononuclear B O
leukocytes B O
major B O
depressive B O
YAFs B O
disorder B O
and B O
HLA-DQ B O
20 B B
healthy B O
mouse B O
T-cell B O
line B O
control B O
subjects B O
circulating B O
mononuclear B O
leukocytes B O
0 B O
The B B
NF-Y B I
number B I
of B O
HLA-D B B
isotypes B O
sites B O
in B O
T-cell B B
line B O
from B O
the B B
circulating B I
mononuclear B O
leukocytes B O
recovered B O
depressed B O
intact B O
trimeric B O
complex B B
group B O
was B O
HLA-D B O
genes B O
not B O
significantly B O
Jurkat B O
cells B B
different B O
from B O
lymphoid B B
cells B I
that B O
of B O
native B B
NF-YA B O
: B O
B B O
: B O
C B O
complex B O
the B B
control B O
promoter B O
III B O
group B O
0 B O
T-cell B O
line B O
Although B O
the B B
macrophage B I
mean B O
plasma B O
transcriptional B O
cofactor B O
cortisol B O
concentration B O
CIITA B O
gene B O
in B O
recovered B B
monocytic B O
cell B O
line B B
depressives B O
was B O
lymphoid B O
tissue B O
higher B O
than B O
PC4 B O
in B O
control B B
CIITA B O
promoter B B
III B I
subjects B I
Mono B B
Mac B I
6 B O
monocytic/macrophage B O
cell B O
line B O
the B B
difference B I
lymphocyte B O
only B O
just B B
high B O
affinity B O
NF-Y B O
reached B O
significance B O
CIITA B O
0 B O
This B O
Mono B O
Mac B O
6 B O
cells B O
study B O
shows B O
Lymphocytes B O
that B O
the B B
anion B O
exchangers B O
reduction B O
in B O
promoter B B
III B O
numbers B O
which B B
Mono B O
Mac B O
6 B O
cells B O
occurs B O
during B O
T B O
helper B O
cell B O
acute B O
depressive B O
NF-Y B O
illness B O
does B O
IL-2 B O
gene B O
not B O
persist B O
Mono B O
Mac B O
6 B O
cells B O
on B O
recovery B O
Natural B O
Killer B B
cells B I
and B I
is B I
PC4 B I
therefore B B
major B I
histocompatibility B O
complex B O
( B O
MHC B B
) B I
region B I
state-dependent B B
Mono B I
Mac B O
6 B O
cells B O
0 B O
Identification B B
lymphocyte B I
and B I
purification B I
NF-Y B I
of B O
a B B
genome B I
( B I
) B O
T B O
cell B O
line B O
that B O
activates B B
normal B O
and B O
leukaemic B O
peripheral B O
leucocytes B O
transcription B O
of B O
C-terminal B B
region B O
an B B
in B O
MHC B B
genomic B O
region B O
vitro B O
0 B O
T-cell B O
lines B O
The B B
octamer B O
leukaemic B O
cells B O
sequence B B
5'-ATGCAAAT B I
PC4 B I
in B B
pericentromeric B I
heterochromatin B O
either B O
orientation B O
SupT1 B B
T-cell B I
line B I
serves B B
leukaemic B I
cells B I
as B I
an B I
subunit B I
interaction B I
subdomain B I
in B O
a B B
lymphocyte-specific B I
TdT B I
promoter B I
variety B I
of B O
CD3/CD28-costimulated B B
Jurkat B I
T B I
cells B I
and B O
also B O
NK B O
cell B O
occurs B O
as B B
highly B I
conserved B O
DNA B O
binding-subunit B O
interaction B O
domain B O
a B B
0 B I
integrated B I
TdT B O
promoter B O
It B O
is B O
Jurkat B O
T B O
cells B O
of B O
particular B B
lymphoid B O
cell B O
interest B B
in B O
DBD B B
since B O
it B O
TdT B O
promoter B B
is B I
found B I
